10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2008

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-16185

GEOPHARMA, INC.

(Exact name of registrant as specified in its charter)

State of Florida	59-2600232
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

6950 Bryan Dairy Road, Largo, Florida	33777
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (727) 544-8866

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    x  Yes    ¨  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    ¨  Yes    x   No

The number of shares outstanding of the Issuer’s common stock at $.01 par value as of February 6, 2009 was 18,011,873.

PART I – FINANCIAL INFORMATION

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

GEOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	December 31, 2008			March 31, 2008
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	324,739		$	523,802
Certificate of deposit		5,036,489			6,001,946
Accounts receivable, net		4,078,702			7,708,349
Accounts receivable, other		354,955			324,234
Inventories, net		11,496,887			13,614,824
Prepaid expenses and other current assets		543,996			1,186,289
Due from affiliates		—			37,471
Total current assets	$	21,835,768		$	29,396,915
Property, plant, leasehold improvements and equipment, net		12,358,634			13,374,250
Goodwill, net		13,425,493			13,425,493
Deferred compensation		3,337,578			2,158,291
Intangible assets, net		7,670,222			6,432,954
Deferred tax asset, net		4,965,200			3,188,200
Other assets, net		1,295,991			1,038,891
Total assets	$	64,888,886		$	69,014,994
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	8,647,549		$	12,728,936
Credit line payable		2,214,000			1,856,000
Notes payable		5,541,840			5,849,490
Current portion of long-term obligations		2,861,551			2,700,110
Accrued expenses and other liabilities		6,249,212			5,108,913
Related party obligation		150,414			—
Total current liabilities	$	25,664,566		$	28,243,449
Long-term obligations, less current portion, and deferred revenue		1,419,109			786,889
Total liabilities	$	27,083,675		$	29,030,338
Convertible debt		15,000,000			10,000,000
Commitments and contingencies
Minority interest		(2,336,770	)		(1,812,461	)
Shareholders’ equity:
6% convertible preferred stock, Series B, $.01 par value (3,975 and 5,000 shares authorized, 5,000 shares issued and outstanding (liquidation preference $5,000,000)		40			50
Common stock, $.01 par value; 24,000,000 shares authorized; 17,600,464 and 14,380,387 shares issued and outstanding		176,005			143,804
Treasury stock (65,428 common shares, $.01 par value)		(654	)		(654	)
Additional paid-in capital		66,523,634			62,161,427
Retained earnings (deficit)		(41,557,044	)		(30,507,510	)
Total shareholders’ equity	$	25,141,981		$	31,797,117
Total liabilities and shareholders’ equity	$	64,888,886		$	69,014,994

See accompanying notes to condensed consolidated financial statements.

GEOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended December 31,						Nine Months Ended December 31,
	2008			2007			2008			2007
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Revenues:
Distribution	$	8,527,211		$	11,217,987		$	33,116,852		$	14,435,258
Manufacturing		4,081,800			7,019,351			14,898,770			16,601,874
Pharmaceutical		503,961			—			1,162,405			41,188
Total revenues	$	13,112,972		$	18,237,338		$	49,178,027		$	31,078,320
Cost of goods sold:
Distribution		7,050,357			9,042,503			26,856,387			10,779,944
Manufacturing (excluding depreciation and amortization presented below)		2,865,372			4,790,637			10,535,463			11,578,661
Pharmaceutical		946,836			828,743			3,060,320			2,402,125
Total cost of goods sold	$	10,862,565		$	14,661,883		$	40,452,170		$	24,760,730
Gross profit:
Distribution		1,476,854			2,175,484			6,260,465			3,655,314
Manufacturing		1,216,428			2,228,714			4,363,307			5,023,213
Pharmaceutical		(442,875	)		(828,743	)		(1,897,915	)		(2,360,937	)
Total gross profit	$	2,250,407		$	3,575,455		$	8,725,857		$	6,317,590
Selling, general and administrative expenses:
Selling, general and administrative expenses		5,244,248			5,100,221			16,991,035			11,406,989
Stock compensation expense		368,067			266,658			1,042,484			687,495
Depreciation and amortization		728,140			487,050			2,121,152			1,306,409
Total selling, general and administrative expenses	$	6,340,455		$	5,853,929		$	20,154,671		$	13,400,893
Operating income (loss) before other income and expense, minority interest, income taxes and discontinued operations	$	(4,090,048	)	$	(2,278,474	)	$	(11,428,814	)	$	(7,083,303	)
Other income (expense), net:
Interest income (expense), net		(537,170	)		(240,311	)		(1,516,405	)		(313,277	)
Other income (expense), net		6,346			10,793			20,176			11,318
Total other income (expense), net	$	(530,824	)	$	(229,518	)	$	(1,496,229	)	$	(301,959	)
Income (loss) before minority interest, income taxes and discontinued operations	$	(4,620,872	)	$	(2,507,992	)	$	(12,925,043	)	$	(7,385,262	)
Minority interest benefit (expense)		153,885			202,495			524,309			644,951
Income tax benefit (expense)		158,300			729,951			1,776,200			2,415,353
Net income (loss) from continuing operations	$	(4,308,687	)	$	(1,575,546	)	$	(10,624,534	)	$	(4,324,958	)
Discontinued operations:
Revenues: PBM	$	—		$	—		$	—		$	2,925,139
Cost of goods sold: PBM		—			—			—			2,904,274
Gross profit: PBM	$	—		$	—		$	—		$	20,865
Selling, general and administrative expenses: PBM		—			—			—			20,785
PBM segment exit income (expense)		—			—			—			8,300
Discontinued operations net income (net of income tax)	$	—		$	—		$	—		$	8,380

Net income (loss)	$	(4,308,687	)	$	(1,575,546	)	$	(10,624,534	)	$	(4,316,578	)
Preferred stock dividends		137,701			100,001			425,001			308,336
Net income (loss) available to common shareholders	$	(4,446,388	)	$	(1,675,547	)	$	(11,049,535	)	$	(4,624,914	)
Basic income (loss) per share	$	(0.26	)	$	(0.12	)	$	(0.63	)		(0.39	)
Basic weighted average number of common shares outstanding		17,102,350			13,805,912			17,535,036			11,967,112
Diluted income (loss) per share	$	(0.26	)	$	(0.12	)	$	(0.63	)	$	(0.39	)
Diluted weighted average number of common shares outstanding		17,102,350			13,805,912			17,535,036			11,967,112
Basic and diluted discontinued operations earnings per share	$	—		$	—		$	—		$	—

See accompanying notes to condensed consolidated financial statements.

GEOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	December 31, 2008			December 31, 2007
	(Unaudited)			(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	(10,624,534	)	$	(4,316,578	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation, leasehold and intangible amortization		2,121,152			1,306,409
Income tax expense (benefit)		(1,776,200	)		(2,415,353	)
Amortization of stock deferred compensation		1,042,484			687,495
Accrued interest income		(34,543	)		(243,245	)
Common stock issued for interest payment		845,522			—
Common stock issued for payment of consulting fees		24,000			—
Changes in operating assets and liabilities:
Accounts receivable, net		3,629,647			3,297,405
Accounts receivable, other		(30,721	)		(76,786	)
Inventories, net		2,117,937			(1,070,686	)
Prepaid expenses and other current assets		814,500			385,800
Deferred tax asset, net		(800	)		77,348
Other assets, net		(46,575	)		94,233
Accounts payable		(4,081,387	)		1,034,635
Accrued expenses and other payables		2,034,507			(294,950	)
Due from affiliates, net		37,471			558,596
Net cash provided by (used in) operating activities	$	(3,927,540	)	$	(975,677	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, leasehold improvements and equipment	$	(525,442	)	$	(2,293,973	)
Purchase of certificate of deposit		—			(7,007,000	)
Purchase of intangible assets		(1,552,471	)		(1,293,077	)
Issuance of note receivable to Dynamic Health Products, Inc., prior to acquisition		—			(3,527,966	)
Cash acquired upon acquisition of Dynamic Health Products, Inc.		—			1,290,137
Proceeds from certificate of deposit maturity		1,000,000			1,007,000
Proceeds (uses) due to minority interest investment, net		(524,309	)		(644,950	)
Repayments of notes receivable		12,955			10,324
Net cash provided by (used in) investing activities	$	(1,589,267	)	$	(12,459,505	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from private placement – Convertible debt	$	5,000,000		$	10,000,000
Proceeds from private placement – Common stock issuance		—			2,500,000
Proceeds (repayments) from credit line, net		358,000			(1,533,000	)
Proceeds from vested stock options exercised		8,500			4,250
Proceeds from issuance of short-term obligations		—			4,000,000
Proceeds from issuance of long-term obligations		450,829			—
Proceeds from issuance of related party obligation		150,414			—
Payments for private placement fees		(24,603	)		(989,078	)
Payments of acquisition costs		—			(221,956	)
Payments of short-term obligations		(479,857	)		—
Payments of long-term obligations		(145,539	)		(660,342	)
Net cash provided by (used in) financing activities	$	5,317,744		$	13,099,874
Net increase (decrease) in cash	$	(199,063	)	$	(335,308	)
Cash at beginning of period		523,802			735,000
Cash at end of period	$	324,739		$	399,692

SUPPLEMENTAL INFORMATION:
Cash paid for interest	$	380,384	$	182,396
Cash paid for income taxes	$	—	$	—
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Value of common stock issued to pay preferred stock dividends	$	425,001	$	308,336
Value of restricted common stock issued for deferred compensation	$	2,221,771	$	—
Value of common stock issued for payment of accrued interest expense	$	805,433	$	—
Value of common stock issued for payment of consulting fees	$	24,691	$	—
Value of common stock issued for employee benefit plan	$	70,605	$	95,852
Value of common stock issued in conversion of preferred stock	$	94,037	$	—
Issuance of short-term obligations for prepaid expenses	$	172,207	$	120,736
Increase in other assets and deferred revenue	$	488,370	$	—
Value of common stock issued for acquisition of Dynamic Health Products, Inc.	$	—	$	8,515,761

See accompanying notes to condensed consolidated financial statements.

GEOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2008 AND 2007

(UNAUDITED)

NOTE 1 – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instruction to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended December 31, 2008 and 2007 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2009. For further information, refer to the consolidated financial statements and footnotes included in the Company’s Form 10-K as of and for the years ended March 31, 2008 and 2007 as filed with the Securities and Exchange Commission on June 30, 2008.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

a. Principles of Consolidation

The condensed consolidated financial statements as of and for the three and nine months ended December 31, 2008 include the accounts of GeoPharma, Inc. (the “Company”), (“GeoPharma”), which is continuing to do manufacturing business as Innovative Health Products, Inc. (“Innovative”), and its wholly-owned subsidiaries IHP Marketing, Inc. (“IHP Marketing”), Breakthrough Engineered Nutrition, Inc. (“Breakthrough”), Breakthrough Marketing, Inc. (“Breakthrough Marketing”), Belcher Pharmaceuticals, Inc. (“Belcher”), Belcher Capital Corporation (“Belcher Capital”), Go2PBM Services, Inc. (“PBM”), Libi Labs, Inc. (“Libi Labs”) and its 51% owned LLC, American Antibiotics, which is accounted for given the consideration of the 49% minority interest, EZ-Med Company (“EZ-Med”), Dynamic Health Products, Inc. (“BOSS”) and Acellis Biosciences, Inc. (“Acellis”), a Florida corporation. Acellis began operations in October 2008. All transactions relating to significant intercompany balances and transactions have been eliminated in consolidation.

The consolidated financial statements as of and for the three and nine months ended December 31, 2007 include the accounts of GeoPharma, which is continuing to do manufacturing business as Innovative and its wholly-owned subsidiaries IHP Marketing, Breakthrough, Breakthrough Marketing, Belcher, Belcher Capital, PBM, Libi Labs and its 51% owned LLC, American Antibiotics, which is accounted for given the consideration of the 49% minority interest. Effective June 14, 2007, the Company acquired EZ-Med, a Florida corporation. Effective October 16, 2007, the Company acquired Dynamic Health Products, Inc., a Florida corporation, and its wholly-owned subsidiaries, consisting of Online Meds Rx, Inc., Herbal Health Products, Inc., Pharma Labs Rx, Inc., Bob O’Leary Health Food Distributor Co., Inc. and Dynamic Marketing I, Inc. All transactions relating to significant intercompany balances and transactions have been eliminated in consolidation.

b. Industry Segments

In accordance with the provisions of Statement of Financial Accounting Standards No. 131, (SFAS 131), “Disclosures about Segments of an Enterprise and Related Information”, a company is required to disclose selected financial and other related information about its operating segments. Operating segments are components of an enterprise about which separate financial information is available and is utilized by the chief operating decision maker (“CODM”) related to the allocation of resources and in the resulting assessment of the segment’s overall performance. The measure used by the Company’s CODM is a business segment’s gross profit. As of and for the three and nine months ended December 31, 2008, and as of March 31, 2008, the Company had three industry segments that accompany corporate: manufacturing, distribution and pharmaceutical. For the three and nine months ended December 31, 2007, the Company had four industry segments that accompany corporate: manufacturing, distribution, pharmaceutical and pharmacy benefit management. Effective May 15, 2007, the Company mutually terminated its Pharmacy Benefit Management contract with AmeriGroup, formerly known as CarePlus, and as a result, the pharmacy benefit management segment was therefore ended. See further consideration in Note 14.

Each of the business segments total revenues for the three and nine months ended December 31, 2008 and 2007 are presented on the face of the statements of operations. The $64,888,886, of total assets as of December 31, 2008 were comprised of $19,307,798 attributable to corporate, $11,846,616 attributable to manufacturing, $18,047,149 attributable to distribution, and $15,687,323 attributable to pharmaceutical. The $69,014,994, of total assets as of March 31, 2008 were comprised of $16,079,021 attributable to corporate, $14,280,086 attributable to manufacturing, $22,803,336 attributable to distribution, and $15,852,551 attributable to pharmaceutical.

c. Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

d. Certificate of Deposit

The certificate of deposit amounting to $5,036,489 at December 31, 2008 earns interest at a rate of 3.16% per annum, matures on October 8, 2009, and has been assigned as collateral for the $5 million note payable to First Community Bank of America, due on October 6, 2009. See Note 9.

e. Accounts Receivable

Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. In determining collectability, historical trends are evaluated and specific customer issues are reviewed to arrive at appropriate allowances.

f. Inventories

Inventories, net, are stated at lower of cost or market. Cost is determined using the first-in, first-out method (“FIFO”).

g. Property, Plant, Leasehold Improvements and Equipment

Depreciation is provided for using the straight-line method, in amounts sufficient to relate the cost of depreciable assets to operations over their estimated service lives (asset categories range from three to thirty-nine years). Leasehold improvements are amortized using the straight-line method over the lives of the respective leases or the service lives of the improvements, whichever is shorter. Leased equipment under capital leases is amortized using the straight-line method over the lives of the respective leases or over the service lives of the assets, whichever is shorter, for those leases that substantially transfer ownership. Accelerated depreciation methods are used for tax purposes.

h. Intangible Assets

Intangible assets consist primarily of goodwill, loan costs, customer lists, a distributor agreement and intellectual property (including generic drug ANDAs). Statement of Financial Accounting Standards No. 142, “Goodwill and Other Intangibles” (SFAS 142) requires that goodwill and intangible assets with indefinite useful lives no longer be amortized, but instead be tested for impairment at least annually. The Company has selected January 1 as the annual date to test these assets for impairment. SFAS 142 also requires that intangible assets with definite useful lives be amortized over their respective estimated useful lives, and reviewed for impairment in accordance with SFAS No. 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of”. The unamortized balance of the intellectual property, including generic drug ANDAs, as of December 31, 2008 and March 31, 2008 was $5,613,935 and $5,224,979, respectively. Based on the required analyses performed as of that annual test date, no impairment loss was required to be recorded for the fiscal year ended March 31, 2008.

For the three and nine months ended December 31, 2008 and 2007, amortization expense associated with goodwill was $0. The unamortized balance of goodwill at December 31, 2008 and March 31, 2008 was $13,425,493. No impairment loss was required to be recorded.

i. Impairment of Assets

In accordance with the provisions of Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (SFAS 144), the Company’s policy is to evaluate whether there has been a permanent impairment in the value of long-lived assets, certain identifiable intangibles and goodwill when certain events have taken place that indicate the remaining unamortized balance may not be recoverable. When factors indicate that the intangible assets should be evaluated for possible impairment, the Company uses an estimate of related undiscounted cash flows. There have been no impairment losses recorded.

j. Income Taxes

The Company utilizes the guidance provided by Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” (SFAS 109). Under the liability method specified by SFAS 109, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities.

k. Earnings (Loss) Per Common Share

Earnings (loss) per share are computed using the basic and diluted calculations on the face of the statement of operations. Basic earnings (loss) per share are calculated by dividing net income (loss) available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings (loss) per share is calculated by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, adjusted for the dilutive effect of common stock equivalents, using the treasury stock method. The reconciliation between basic and fully diluted shares for the three and nine months ended December 31, 2008 and 2007 are as follows:

	For the Three Months Ended						For the Nine Months Ended
	December 31, 2008			December 31, 2007			December 31, 2008			December 31, 2007
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Net income (loss) per share – basic:
Net income (loss)	$	(4,446,388	)	$	(1,675,547	)	$	(11,049,535	)	$	(4,624,914	)
Weighted average shares – basic		17,102,350			13,805,912			17,535,036			11,967,112
Net income (loss) per share – basic	$	(0.26	)	$	(0.12	)	$	(0.63	)	$	(0.39	)
Net income (loss) per share – diluted:
Net income (loss)	$	(4,446,388	)	$	(1,675,547	)	$	(11,049,535	)	$	(4,624,914	)
Preferred stock dividends		—			—			—			—
	$	(4,446,388	)		(1,675,547	)	$	(11,049,535	)	$	(4,624,914	)
Weighted average shares – basic		17,102,350			13,805,912			17,535,036			11,967,112
Effect of convertible instruments prior to conversion		—			—			—			—
Effect of warrants prior to conversion		—			—			—			—
Effect of stock options		—			—			—			—
Weighted average shares – diluted		17,102,350			13,805,912			17,535,036			11,967,112
Net income (loss) per share – diluted	$	(0.26	)	$	(0.12	)	$	(0.63	)	$	(0.39	)

For the three months ended December 31, 2008, 4,352,064 shares issuable upon conversion of convertible instruments, warrants on 1,105,923 shares of common stock and 1,866,518 shares issuable upon exercise of stock options were not included in the computation of diluted earnings (loss) per share because their effects were anti-dilutive. For the three months ended December 31, 2007, 3,440,367 shares issuable upon conversion of convertible instruments, warrants on 1,105,923 shares of common stock and 1,871,528 shares issuable upon exercise of stock options were not included in the computation of diluted earnings (loss) per share because their effects were anti-dilutive.

For the nine months ended December 31, 2008, 4,352,064 shares issuable upon conversion of convertible instruments, warrants on 1,105,923 shares of common stock and 1,866,518 shares issuable upon exercise of stock options were not included in the computation of diluted earnings (loss) per share because their effects were anti-dilutive. For the nine months ended December 31, 2007, 3,365,304 shares issuable upon conversion of convertible instruments, warrants on 1,105,923 shares of common stock and 1,871,528 shares issuable upon exercise of stock options were not included in the computation of diluted earnings (loss) per share because their effects were anti-dilutive.

l. Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles, requires management to make estimates, assumptions and apply certain critical accounting policies that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at December 31, 2008 and March 31, 2008, as well as the reported amounts of revenues and expenses for the three and nine months ended December 31, 2008 and 2007. Estimates and assumptions used in our financial statements are based on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. These estimates and assumptions also require the application of certain accounting policies, many of which require estimates and assumptions about future events and their effect on amounts reported in the financial statements and related notes. We periodically review our accounting policies and estimates and make adjustments when facts and circumstances dictate. Actual results may differ from these estimates under different assumptions or conditions. Any differences may have a material impact on our financial condition, results of operations and cash flows.

m. Concentration of Credit Risk

Concentrations of credit risk with respect to trade accounts receivable are customers with balances that exceed 5% of total consolidated trade accounts receivable, net. At December 31, 2008, four customers, Central Coast Nutraceuticals with 13.1%, Spectrum Group with 12.4%, Walgreens with 8.9% and Intelligent Beauty, LLC with 7.4% of the total of consolidated trade accounts receivable, net. At March 31, 2008, five customers, Walgreens with 10.2%, General Nutrition Distribution with 8.9%, Spectrum Group with 8.5%, ITV Global, Inc. with 7.1% and Berkeley Premium Nutraceuticals with 5.5% of the total of consolidated trade accounts receivable, net.

For the three months ended December 31, 2008, two customers individually exceeded 5% of our total consolidated revenues which included Central Coast Nutraceuticals for 14.2% and DPS Nutrition Inc. for 8.4%, in relation to total consolidated revenues, and for the three months ended December 31, 2007, three customers individually exceeded 5% of our total consolidated revenues which included Jacks Distribution for 5.4%, Nutracea for 6.7% and DPS Nutrition Inc. for 7.8%, in relation to total consolidated revenues.

For the nine months ended December 31, 2008, two customers individually exceeded 5% of our total consolidated revenues, DPS Nutrition Inc. for 7.5% and Central Coast Nutraceuticals for 5.6%, in relation to total consolidated revenues, and for the nine months ended December 31, 2007, one customer individually exceeded 5% of our total consolidated revenues, Jacks Distribution for 10.2%, in relation to total consolidated revenues.

The Company has no concentration of customers within specific geographic areas outside the United States that would give rise to significant geographic credit risk.

As March 31, 2008, the Company maintained cash balances in excess of federally insured limits of $6,006,411, including the Company’s certificate of deposit. As of December 31, 2008, none of the Company’s cash balances were in excess of federally insured limits.

n. Revenue and Cost of Goods Sold Recognition

In accordance with Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), revenues are recognized by the Company when the merchandise is shipped which is when title and risk of loss has passed to the external customer. The Company analyzes the status of the allowance for uncollectible accounts based on historical experience, customer history and overall credit outstanding. For our distribution segment, any charge backs or other sales allowances immediately reduce the gross receivable with the corresponding reduction effected through increases in sales allowances which directly reduce sales revenue. For our PBM segment, service revenues are recognized once the member service of completing and fulfilling delivery of the members’ prescription.

Cost of goods sold is recognized by the Company simultaneously with the recognition of revenues with a direct charge to cost of goods sold and with an equal reduction to inventory at FIFO cost. For the discontinued PBM segment, cost of goods sold was recognized based on actual costs incurred and was recognized as the related revenue was recognized.

Provisions for discounts and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Sales incentives to customers and returns have thus far been immaterial to the Company. All shipping and handling costs invoiced to customers are included in revenues.

Costs incurred by BOSS for shipping, handling and warehousing are included in selling, general and administrative expenses in the statements of operations were $335,236 and $400,533 for the three months ended December 31, 2008 and 2007, respectively, and $1,230,694 and $400,533 for the nine months ended December 31, 2008 and 2007, respectively.

o. Advertising Costs

In accordance with Statement of Position No. 93-7, “Reporting on Advertising Costs” (SOP 93-7), the Company charges advertising costs, including those for catalog sales and direct mail, to expense as incurred. Advertising expenses are included in selling, general and administrative expenses in the statements of operations and were $206,030 and $174,370 for the three months ended December 31, 2008 and 2007, respectively, with $1,357,332 and $476,696 of advertising expenses for the nine months ended December 31, 2008 and 2007, respectively.

For cooperative advertising allowances received from third party manufacturers and vendors, the Company applies EITF Issue No. 02-16 “Accounting by a Customer (Including a Reseller) for Certain Consideration Received from a Vendor”. These allowances are included as a reduction in cost of goods sold and were zero for the three months ended December 31, 2008 and 2007, respectively, and $222,300 and zero for the nine months ended December 31, 2008 and 2007, respectively.

p. Research and Development Costs

Costs incurred to develop our generic pharmaceutical products are expensed as incurred and charged to research and development (“R&D”). R&D expenses for the three months ended December 31, 2008 and 2007 were $307,638 and $309,850, respectively, and were $1,459,539 and $992,548 for the nine months ended December 31, 2008 and 2007.

q. Fair Value of Financial Instruments

The Company, in estimating its fair value disclosures for financial instruments, uses the following methods and assumptions:

Cash, Accounts Receivable, Accounts Payable and Accrued Expenses: The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate their fair value due to their relatively short maturity.

Short-term and Long-term Obligations: The fair value of the Company’s fixed-rate short-term and long-term obligations are estimated using the discounted cash flow analyses, based on the Company’s current incremental borrowing rates for similar types of borrowing arrangements. At December 31, 2008 and March 31, 2008, the fair value of the Company’s short-term and long-term obligations approximated their carrying value.

Credit Line Payable: The carrying amount of the Company’s credit line payable approximates fair market value since the interest rate on this instrument corresponds to market interest rates.

r. Reclassifications

Certain reclassifications have been made to the financial statements as of March 31, 2008 and as of and for the three and nine months ended December 31, 2007 to conform to the presentation as of and for the three and nine months ended December 31, 2008.

s. Stock-Based Compensation

Effective April 1, 2006, the Company was required to adopt Statement of Financial Accounting Standards No. 123R, “Share-Based Payment” (SFAS 123R) which replaces SFAS 123 and SFAS 148, and supersedes Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (APB No. 25). SFAS 123R requires the cost relating to share-based payment transactions in which an entity exchanges its equity instruments for goods and services from either employees or non-employees be recognized in the financial statements as the goods are received or when the services are rendered. That cost will be measured based on the fair value of the equity instrument issued. See further consideration in Note 13.

SFAS 123R now applies to all of our existing outstanding unvested share-based payment stock option awards as well as any and all future awards. We elected to use the modified prospective transition as opposed to the modified retrospective transition method such that financial statements prior to adoption remain unchanged. The Black-Scholes option pricing model was applied to value the Company’s stock option compensation expense as was used by the Company previously in the pro forma disclosures.

NOTE 3 – ACCOUNTS RECEIVABLE, NET

Accounts receivable, net, consist of the following:

	December 31, 2008			March 31, 2008
	(Unaudited)
Trade accounts receivable	$	4,869,756		$	8,265,656
Less allowance for uncollectible accounts		(791,054	)		(557,307	)
	$	4,078,702		$	7,708,349

As of December 31, 2008, the total accounts receivable balance of $4,869,756 includes $2,597,569 related to the Company’s manufacturing segment, $1,869,958 related to the Company’s distribution segment and $402,229 related to the Company’s pharmaceutical segment. As of March 31, 2008, the total accounts receivable balance of $8,265,656 includes $4,366,462 related to the Company’s manufacturing segment, $3,606,559 related to the Company’s distribution segment and $292,635 related to the Company’s pharmaceutical segment.

The Company recognizes revenues for product sales when title and risk of loss pass to its external customers and analyzes the status of the allowance for uncollectible accounts based on historical experience, customer history and overall credit outstanding. For our distribution segment, any charge backs or other sales allowances immediately reduce the gross receivable with the corresponding reduction effected through increases in sales allowances which directly reduce sales revenue.

NOTE 4 – INVENTORIES, NET

Inventories, net, consist of the following:

	December 31, 2008			March 31, 2008
	(Unaudited)
Processed raw materials and packaging	$	5,188,358		$	5,461,487
Work in process		545,588			602,258
Finished goods		5,865,316			7,649,696
	$	11,599,262		$	13,713,441
Less reserve for obsolescence		(102,375	)		(98,617	)
	$	11,496,887		$	13,614,824

As of December 31, 2008, the total inventory balance of $11,599,262 includes $5,535,759 related to the Company’s manufacturing segment, $4,337,081 related to the Company’s distribution segment and $1,726,422 related to the Company’s pharmaceutical segment. As of March 31, 2008, the total inventory balance of $13,713,441 includes $5,568,602 related to the Company’s manufacturing segment, $6,415,783 related to the Company’s distribution segment and $1,729,056 related to the Company’s pharmaceutical segment.

NOTE 5 – DEFERRED COMPENSATION

The deferred compensation of $3,337,578 and $2,158,291 as of December 31, 2008 and March 31, 2008, respectively, relates to corporate and is amortized over its three-year life, the length of the common stock restriction. The deferred compensation asset relates to shares of 3-year restricted common stock issued pursuant to the 2005-2008 Compensation Incentive Plan effective beginning with the fiscal year ended March 31, 2006. The Plan documents the incentive plan and related awards for Plan achievements for the Chairman of the Board of Directors and the Company’s executive officers, which include the Chief Executive Officer, the President, the Senior Vice President/Chief Financial Officer and the Vice President/General Counsel. The asset was recorded based on the number of shares awarded and the discounted fair market value of the restricted stock the date of the award as based on an independent valuation and is amortized over its three-year life, the length of the restriction. See further consideration in Note 13.

NOTE 6 – INTANGIBLE ASSETS, NET

Intangible assets, net consist of the following:

	December 31, 2008			March 31, 2008
	(Unaudited)
Loan and lease costs	$	2,396,849		$	984,291
Intellectual property		2,211,269			1,822,313
Generic drug ANDAs		3,402,666			3,402,666
Patents, trademarks, customer lists and distributor agreement		329,247			315,427
	$	8,340,031		$	6,524,697
Less accumulated amortization		(669,809	)		(91,743	)
	$	7,670,222		$	6,432,954

As of December 31, 2008, the loan and lease costs of $2,396,849 are related to corporate and all of which have an identifiable life and are amortized over that life. Of the $2,211,269 of intellectual property, $200,000 was attributable to the Company’s manufacturing segment, $1,350,396 was attributable to the Company’s distribution segment with the balance of $660,873 being attributable to the Company’s pharmaceutical segment, all of which have no identifiable life and are therefore evaluated annually for impairment. The generic drug ANDAs relate to the pharmaceutical segment and do not have an identifiable life and are therefore evaluated annually for impairment. Of the $329,247 of patents, trademarks, customer lists and distribution agreement, $42,896 related to the Company’s manufacturing segment, $279,136 related to the Company’s distribution segment and $7,215 related to the Company’s pharmaceutical segment.

As of March 31, 2008, the loan and lease costs of $984,291 are related to corporate and all of which have an identifiable life and are amortized over that life. Of the $1,822,313 of intellectual property, $200,000 was attributable to the manufacturing segment, $1,200,396 was attributable to the distribution segment with the balance of $421,917 being attributable to the pharmaceutical segment, all of which have no identifiable life and are therefore evaluated annually for impairment. The generic drug ANDAs relate to the pharmaceutical segment and do not have an identifiable life and are therefore evaluated annually for impairment. Of the $315,427 of patents, trademarks, customer lists and distribution agreement, $31,121 relates to the manufacturing segment, $279,136 relates to the distribution segment and $5,170 relates to the pharmaceutical segment.

As there is an indeterminent life as related to the intellectual property and the generic drug ANDAs, these assets are analyzed each January 1 for impairment.

NOTE 7 – INCOME TAXES

Income taxes for the nine months ended December 31, 2008 and 2007 differ from the amounts computed by applying the effective income tax rates to income before income taxes as a result of the following:

	December 31, 2008			December 31, 2007
	(Unaudited)			(Unaudited)
Computed tax expense (benefit) at the statutory rate (37.63%)	$	(4,666,000	)	$	(2,533,000	)
Increase (decrease) in taxes resulting from:
Effect of permanent differences:
Non deductible		16,000			15,000
Other, net		(103,500	)		(46,000	)

Tax benefits acquired in merger		—			(800,000	)
Change in valuation allowance		2,977,300			949,000
Income tax (benefit) expense	$	(1,776,200	)	$	(2,415,000	)
Temporary differences that give rise to deferred tax assets and liabilities are as follows:
Deferred tax assets:
Bad debts	$	391,100		$	286,000
Inventories		38,500			37,000
Accrued vacation		66,300			54,000
Deposits		183,800			111,000
Deferred rent		163,400			163,000
Net operating loss carryforwards		8,216,000			3,215,000
Stock option cancellation and restricted stock		1,203,900			723,000
	$	10,263,000		$	4,589,000
Valuation allowance		(5,035,600	)		(1,158,000	)
Deferred tax asset	$	5,227,400		$	3,431,000
Deferred tax liabilities:
Fixed and intangible asset basis differences	$	(162,700	)	$	(214,000	)
Inventory capitalization		(99,500	)		(125,000	)
		(262,200	)	$	(339,000	)
Net deferred tax asset (liability) recorded	$	4,965,200		$	3,092,000

At December 31, 2008 and 2007, the Company has a net operating loss carryforward of approximately $21,834,000 and $5,900,000, respectively, to offset future taxable income. The tax net operating loss carryforwards begin to expire in 2021.

The Company adopted Financial Standards Board Interpretation No. 48, “Accounting for Income Taxes” (FIN 48). As a result of the adoption of FIN 48, the Company has not recognized a material adjustment in the liability for unrecognized tax benefits and has not recorded any provision for penalties or interest related to uncertain tax positions.

NOTE 8 – CREDIT LINE PAYABLE

On October 12, 2007, BOSS issued a revolving Promissory Note (“Note”) to Wachovia Bank, National Association (“Wachovia”), in the amount of $4 million or such sum as may be advanced and outstanding from time to time, pursuant to the Loan Agreement. Interest shall accrue on the unpaid principal balance and varies based on the LIBOR Market Index Rate plus 1.75%, for any day. The note is due and payable in consecutive monthly payments of accrued interest only, commencing on November 20, 2007, and continuing on the same day of each month thereafter until fully paid. In any event, all principal and accrued interest shall be due and payable on August 31, 2008. On March 28, 2008, the Company entered into loan modification agreements with Wachovia, whereby the amount of the October 12, 2007 revolving Note to Wachovia was reduced from $4 million to $2.5 million, or such sum as may be advanced and outstanding from time to time, and $750,000 of the principal balance of the revolving Note was converted to a term Promissory Note (“Term Note”), both maturing on August 31, 2008. In addition, the rate of interest was modified whereby interest shall accrue on the unpaid principal balance and varies based on the LIBOR Market Index Rate plus 3.15%, for any day. Certain terms of the loan were modified including the financial covenant in regards to the liquidity ratio. On April 25, 2008, we entered into a Modification Number 001 To Loan Agreement and a Modification Number 001 To Promissory Note with Wachovia, whereby certain terms of the loan were modified, including the financial covenant in regards to liquidity ratio. See further consideration in Note 9.

On August 28, 2008, we entered into an Allonge to Promissory Note with Wachovia, with respect to the $2.5 million revolving Note, whereby the rate of interest was modified so that interest shall accrue on the unpaid principal balance and varies based on the Prime Rate plus 2%. “Prime Rate” shall mean the floating annual rate of interest that is designated from time to time by Wachovia as the “Prime Rate” and is used by Wachovia as a reference based with respect to interest rates charged to borrowers. In addition, the maturity date was extended to December 31, 2008. The principal balance was $2,214,000 and $1,856,000, at December 31, 2008 and March 31, 2008, respectively.

The Company is in default on its outstanding obligations to Wachovia under the revolving Note and the Term Note (see Note 9). The notes have not been satisfied since their maturity on December 31, 2008. On January 28, 2009, a Judgment By Confession was entered in favor of Wachovia and against the Company, to compel the Company to satisfy its obligations to Wachovia under the notes, in the amount of $2,753,361, including principal and unpaid interest as of January 21, 2009, damages, costs and attorneys’ fees. The Company is seeking to refinance these obligations with other potential lenders, however there can be no assurance that the Company will be able to obtain alternative financing on terms acceptable to it or at all, particularly in light of the current economic and financial market environment, in which event the Company will need to consider all available alternatives.

NOTE 9 – NOTES PAYABLE (SHORT-TERM)

On April 6, 2008, the Company entered into a Change In Terms Agreement with First Community Bank of America (“FCB”), whereby the $3,500,000 promissory note issued to FCB on October 1, 2007 was modified and consolidated with the $500,000 promissory note issued to FCB on December 20, 2007 and the $1,000,000 promissory note issued to FCB on January 18, 2008. In accordance with the modified terms, interest on the note is payable monthly in arrears, commencing May 6, 2008, at the rate of 5.15% per annum, with the entire principal payment of $5,000,000 plus interest being due on October 6, 2008. In connection with the promissory note, the Company assigned, as collateral security for the note, a certificate of deposit account with FCB in the approximate balance of $6,246,771 as of January 18, 2008, including interest thereon. On October 6, 2008, the Company entered into a Change In Terms Agreement with FCB, whereby the terms of the promissory note were modified so that interest on the note is payable monthly in arrears, commencing November 6, 2008, at the rate of 5.21% per annum, with the entire principal payment of $5,000,000 plus interest being due on October 6, 2009.

On March 28, 2008, the Company entered into modification agreements with Wachovia, whereby $750,000 of the principal balance of the October 12, 2007 revolving Promissory Note issued by BOSS to Wachovia was converted to a Term Note, maturing on August 31, 2008. Interest shall accrue on the unpaid principal balance and varies based on the LIBOR Market Index Rate plus 3.15%, for any day. The Term Note is due and payable in consecutive monthly payments of principal equal to $50,000 plus accrued interest, commencing on May 1, 2008 and continuing on the same day of each month thereafter until fully paid. In any event, all principal and accrued interest shall be due and payable on August 31, 2008. On April 25, 2008, we entered into a Modification Number 001 to Loan Agreement and a Modification Number 001 To Promissory Note with Wachovia, whereby certain terms of the loan were modified, including the financial covenant in regards to liquidity ratio. See further consideration in Note 8.

On August 28, 2008, we entered into an Allonge to Promissory Note with Wachovia, with respect to the $750,000 Term Note, whereby the rate of interest was modified so that interest shall accrue on the unpaid principal balance and varies based on the Prime Rate plus 2%. “Prime Rate” shall mean the floating annual rate of interest that is designated from time to time by Wachovia as the “Prime Rate” and is used by Wachovia as a reference based with respect to interest rates charged to borrowers. In addition, the maturity date was extended to December 31, 2008. The principal balance was $400,000 and $750,000, at December 31, 2008 and March 31, 2008, respectively.

The Company is in default on its outstanding obligations to Wachovia under the revolving Note (see Note 8) and the Term Note. The notes have not been satisfied since their maturity on December 31, 2008. On January 28, 2009, a Judgment By Confession was entered in favor of Wachovia and against the Company, to compel the Company to satisfy its obligations to Wachovia under the notes, in the amount of $2,753,361, including principal and unpaid interest as of January 21, 2009, damages, costs and attorneys’ fees. The Company is seeking to refinance these obligations with other potential lenders, however there can be no assurance that the Company will be able to obtain alternative financing on terms acceptable to it or at all, particularly in light of the current economic and financial market environment, in which event the Company will need to consider all available alternatives.

Of the $5,541,840 of short-term obligations outstanding as of December 31, 2008, $5,429,620 related to corporate and $112,220 related to the Company’s distribution segment. Of the $5,849,490 of short-term obligations outstanding as of March 31, 2008, $5,776,159 related to corporate, $36,239 related to the Company’s manufacturing segment and $37,092 related to the Company’s distribution segment.

NOTE 10 – RELATED PARTY OBLIGATION

In September 2008, Jugal Taneja, the Company’s Chairman of the Board of Directors, loaned the Company $150,000. Interest on the note is at the rate of 7% per annum. The balance of the note, together with accrued interest, is due and payable on or before March 31, 2009. Proceeds were used for working capital.

NOTE 11 – LONG-TERM OBLIGATIONS

On September 30, 2008, the Company issued an $800,000 promissory note to First Community Bank of America. The note is payable in six consecutive monthly payments of accrued interest only, commencing on October 30, 2008, and 54 monthly consecutive principal and interest payments of approximately $17,166, commencing April 30, 2009, at the rate of 6.5% per annum. In any event, all principal and accrued interest shall be due and payable on September 30, 2013. The note is secured by equipment as described in a Commercial Security Agreement issued to FCB on September 30, 2008. In addition, Jugal Taneja, the Company’s Chairman of the Board of Directors, assigned, as collateral security for the note, his certificate of deposit account with FCB in the amount of $400,000. Proceeds of the note were used for the purchase of equipment. Future advances under the note are to be used for equipment purchases. The principal balance of the note was $450,829 at December 31, 2008.

Of the $4,280,660 of long-term obligations outstanding as of December 31, 2008, $1,252,390 related to corporate, $31,680 related to the Company’s manufacturing segment, $8,220 related to the Company’s distribution segment and $2,988,370 related to the Company’s pharmaceutical segment. Of the $3,486,999 of long-term obligations outstanding as of March 31, 2008, $907,843 related to corporate, $67,320 related to the Company’s manufacturing segment, $11,836 related to the Company’s distribution segment and $2,500,000 related to the Company’s pharmaceutical segment.

NOTE 12 – CONVERTIBLE DEBT

On April 5, 2007, GeoPharma, Inc. entered into a Note Purchase Agreement, Securities (Common Stock) Purchase Agreement, Convertible Promissory Note, Warrant, and two related Registration Rights Agreements with Whitebox Pharmaceutical Growth Fund, Ltd. (“Whitebox”). In connection with the Whitebox financing, the Company paid a fee to Rodman & Renshaw, LLC equal to $750,000 in cash and a warrant to purchase up to 143,403 shares of the Company’s common stock at an exercise price of $5.23. The transactions contemplated by such agreements were consummated on April 5, 2007, at which time the Company issued the following securities to Whitebox for the following consideration:

• 573,395 shares of common stock, $.01 par value (the “Common Stock”), at a sales price of $4.36 per share (the “Common Stock Purchase Price”), for a total of $2,500,000;

• A Convertible Promissory Note (the “Note”), with maturity date of April 5, 2013, in the original principal amount of $10,000,000, which amount is convertible into up to 2,293,578 shares of Common Stock at a price of $4.36 per share, subject to certain adjustments as set forth in the Note (the “Conversion Price”); and

• A Warrant to purchase up to 400,000 shares of Common Stock at an exercise of $5.23 per share, subject to certain adjustments as set forth in the Warrant, with a termination date of April 5, 2014.

The Note accrues interest at the rate of 8% per annum, payable on a quarterly basis on January 1, April 1, July 1 and October 1 of each year, beginning on July 1, 2007. Until April 5, 2009, interest is payable by adding the accrued interest to the principal amount of the Note. Following April 5, 2009, interest is payable on each quarterly interest payment date as follows: (i) if funds are legally available for the payment of interest and the Equity Conditions (as defined in the Note and summarized below) have not been met, in cash; (ii) if funds are legally available for the payment of interest and the Equity Conditions have been met, at the sole election of the Company, in cash or shares of Common Stock, which shall be valued solely for such purpose at 95% of the average of the VWAP (as defined below) for the 5 trading days immediately prior to such interest payment date; (iii) if funds are not legally available for the payment of interest and the Equity Conditions have been met, in shares of Common Stock which shall be valued at 95% of the average of the VWAP for the 5 trading days immediately prior to such interest payment date; (iv) if funds are not legally available for the payment of interest and the Equity Conditions have been waived by Whitebox, in shares of Common Stock which shall be valued at 95% of the average of the VWAP for the 5 trading days immediately prior to the interest payment date; and (v) if funds are not legally available for the payment of interest and the Equity Conditions have not been met, then, at the election of Whitebox, such interest payment shall accrue to the next interest payment date or shall be accreted to the outstanding accreted principal amount.

Notwithstanding anything else to the contrary, in the event that (i) the Company’s earnings before interest, income taxes, depreciation, amortization and stock expense, as reported on the Company’s most recent Form 10-Q or Form 10-K (as applicable) is less than $1,250,000 for such quarter, or (ii) the Company’s earnings before interest, income taxes, depreciation, amortization and stock expense for the trailing four quarters is less than $4,000,000 in the aggregate, or (iii) an event or condition that would constitute a Material Adverse Effect (as such term is defined in the Note Purchase Agreement) for the Company shall have occurred, or (iv) the Company shall not have filed its latest Form 10-Q or Form 10-K within the timeframe required by the SEC and the rules and regulations set forth in the Exchange Act, Whitebox shall have the option, in its sole discretion, to require that any interest, for the next subsequent quarterly payment period, be paid in cash.

On April 24, 2008, the Company and Whitebox entered into an Amended and Restated Note Purchase Agreement (the “Restated Note Purchase Agreement”), Amended and Restated Convertible Promissory Note (the “Restated Note”), and Amended and Restated Registration Rights Agreement (the “Restated Registration Rights Agreement” and collectively with the “Restated Note Purchase Agreement and “Restated Note,” the “Restated Agreements”), all of which collectively serve to amend and restate the Original Note, Original Note Purchase Agreement and the Original Registration Rights Agreements. The material amendments contained in the Restated Agreements include the following:

• The Additional Notes contemplated by the Original Note Purchase Agreement have been eliminated and replaced by adding the principal amount of the Additional Notes ($5,000,000) to the Restated Note, thus increasing the total principal amount of the Restated Note to $15,000,000.

• The terms and conditions necessary to satisfy the issuance of the Subsequent Notes contemplated by the Original Note Purchase Agreement have been modified so that Whitebox is now required to make such loan upon the Company’s acquisition of the real estate related to its Beta-Lactam facility (which it currently leases) in Baltimore, Maryland and the satisfaction or waiver of certain other closing conditions related thereto.

• All interest that had accrued on the Original Note from its original issue date (April 5, 2007) through April 24, 2008, in the amount of $865,058, has been converted by Whitebox into a total of 389,666 shares of the Company’s Common Stock in full satisfaction of such accrued interest.

• The interest rate on the Restated Note from and after April 24, 2008 has been increased to 12%, but all of such interest may now be paid, at the option of the Company in shares of common stock of the Company valued at 95% of the volume weighted average

market price of the shares during the 5 trading days immediately preceding the payment of interest, provided that certain “Equity Conditions” (as defined in the Restated Note) have been satisfied. If the Company does not meet the Equity Conditions, and if funds are legally available for the payment of interest, then the Company must pay such interest in cash.

• All requirements that the Company meet certain minimum EBITDA targets have been deleted and replaced by a requirement that the Company’s Current Assets (defined as the sum of (w) 100% of the Company’s cash, plus (x) 100% of the Company’s net accounts receivables plus (y) 50% of the Company’s net inventory plus (z) 30% of the Company’s net property, plant and equipment) exceeds the Company’s Total Debt (defined as indebtedness of the Company and its subsidiaries (x) to Whitebox, (y) under the $4,000,000 revolving promissory note with Wachovia Bank, National Association and (z) under the $5,000,000 promissory note with First Community Bank of America.) If the Company fails to satisfy the foregoing Current Assets Test as of the required date for filing any Form 10-K or Form 10-Q, as applicable (the “Current Assets Test Measurement Date”), Whitebox may require the Company to redeem up to $2,000,000 of the principal amount of the Restated Note as of such Current Assets Test Measurement Date. In addition, if the Company’s Total Debt exceeds the Company’s Current Assets by more than $2,000,000 as of the Current Assets Test Measurement Date, such shortfall will constitute an Event of Default under the Restated Note, in which case the entire outstanding principal amount (including any Accreted Principal or Make-Whole Amounts (as defined by the Restated Note)) under the Restated Note will be due and payable on the 30 ^th day after the occurrence of such default if the Company is unable to cure such default within such thirty (30) day period. The Company is in default of the Current Asset Test requirement as of December 31, 2008.

• The provision of the Original Note Purchase Agreement that allowed Whitebox to put 1/10th of the outstanding principal amount of the Original Note (including any accreted interest) to the Company at par if (A) the sum of the Company’s (i) net accounts receivable, plus (ii) cash and cash equivalents, plus (iii) marketable securities at the end of any quarterly period were less than $7,000,000, or (B) the Company’s revenues were less than $5,000,000 for the most recently reported quarterly period, has been deleted.

• The Company agreed to register all of the shares issuable pursuant to the Restated Note (whether as a result of a conversion or otherwise) to the extent permitted by the SEC in accordance with its rules and regulations.

In connection with the foregoing Restated Agreements, (a) Jugal K. Taneja (the Company’s Chairman of the Board) and certain other purchasers agreed to purchase from Whitebox 373,000 shares of the Company’s common stock, and 260,384 accompanying warrants, issued to Whitebox in connection with the Original Note Purchase Agreement, at a price of $2.22 per share, on or prior to May 7, 2008, and (b) the Company paid to Whitebox a $1,400,000 financing fee in cash.

The offering and sale of the Restated Note (as well as the Original Note and the shares issuable to Whitebox pursuant thereto) were deemed to be exempt under Rule 506 of Regulation D and Section 4(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The offering and sale were made only to one accredited investor, and transfer of the securities has been restricted in accordance with the requirements of the Securities Act of 1933. The Company received written representations from Whitebox regarding, among other things, its accredited-investor status and investment intent.

The Company has received notices from Whitebox alleging two separate defaults under the Restated Note.

The first default letter, dated November 25, 2008, relates to an alleged failure by the Company to use its commercially reasonable efforts to obtain a second priority lien on the assets owned by BOSS, which the Company cannot do without the prior written consent of Wachovia. Wachovia is the primary lender to BOSS. The Company’s obligations to Wachovia matured on December 31, 2008 and are currently in default (see Note 8 and Note 9). Whitebox also takes the position in this letter that as a result of the forgoing alleged default, the Restated Note has been incurring default interest at a rate of 18% since September 20, 2008. Whitebox has since agreed to the interest rate remaining at 12% until March 1, 2009.

The second Whitebox default letter, dated December 5, 2008, relates to an alleged failure by the Company to redeem $2,000,000 of the Restated Note as a result of the Company’s alleged failure to satisfy the Current Asset Test as of September 30, 2008. The Note Purchase Agreement provides that if the Company’s Total Debt exceeds its Current Equity at the end of any fiscal quarter, Whitebox may require the Company to redeem up to $2,000,000 of the principal amount of the Restated Note.

Whitebox could seek repayment, but has given no indication of doing so. The Company is actively involved in negotiations with Whitebox to reach a mutually acceptable arrangement to restructure the financing. There can be no assurance that the Company and Whitebox will reach a mutually acceptable arrangement. If repayment is required, the Company would not have sufficient funds and Whitebox could take legal action to recover amounts due from our assets. Meanwhile, the Company will continue to attempt to reduce expenses and to explore alternate financing arrangements with other potential lenders to refinance all of the Company’s facilities. Again, there can be no assurance that the Company will be able to obtain additional or alternative financing on terms acceptable to it or at all, particularly in light of the current economic and financial market environment, in which event the Company will need to consider all available alternatives.

NOTE 13 – SHAREHOLDERS’ EQUITY

During June 2008, the Compensation Committee of the Company’s Board of Directors, with the approval of the Company’s Board of Directors, awarded the Company’s management a total of 1,532,256 shares of 3-year restricted Company common stock pursuant to the 2005-2008 Compensation Incentive Plan. As a result, the Company recorded a deferred compensation asset of approximately $2,221,771, which is being amortized over 36 months to stock compensation expense within selling, general and administrative expenses on the Company’s statements of operations. See further consideration in Note 5.

On September 29, 2008, the Company issued 51,208 shares of common stock to GeoPharma, Inc. 401(k) Plan, for the Company’s $70,605 contribution to the employees 401(k) benefit plan for the fiscal year 2008.

On December 8, 2008, a holder of 1,025 shares of Company 6% convertible preferred stock, Series B, $.01 par value, converted such shares into 235,092 shares of Company common stock, at a set conversion price of $4.36 per common share. The closing price of the Company’s common stock was $.40 at the close of business for the Nasdaq Capital Market on December 5, 2008.

NOTE 14 – DISCONTINUED OPERATIONS

As presented on the face of the statement of operations under “Discontinued operations”, effective May 15, 2007, the Company mutually terminated its Pharmacy Benefit Management and Services Agreement (the “Agreement”). Under the Agreement, the Company previously managed AmeriGroup’s (formerly known as CarePlus) health care plan members and administrated the members’ related pharmacy claims. No amounts were due from or due to AmeriGroup and therefore, the business segment will not continue.

NOTE 15 – LITIGATION

On September 29, 2006, Schering Corporation (“Schering”) filed an action in the United States District Court for the District of New Jersey, against Belcher Pharmaceuticals, Inc. and GeoPharma, Inc. (along with nineteen other defendants) alleging that the filing of Belcher Pharmaceuticals’ Abbreviated New Drug Application (“ANDA”) for 5 mg Desloratadine Tablets, AB-rated to Clarinex ^® , infringed U.S. Patent No. 6,100,274 (“the ‘274 patent”) Case No. 3:06-cv-04715-MLC-TJB. On November 8, 2006, Belcher filed a motion to dismiss in the New Jersey case for lack of jurisdiction. On October 5, 2006 Schering filed an action in the United States District Court for the Middle District of Florida, Tampa Division, Case No. 8:06-cv-01843-SCB-EAJ, against Belcher Pharmaceuticals, Inc. and GeoPharma, Inc. alleging that the filing of Belcher Pharmaceuticals’ ANDA for 5 mg Desloratadine Tablets, AB-rated to Clarinex ^® , infringed the ‘274 patent. On February 14, 2008 Belcher and Schering entered into a stipulation to withdraw the motion to dismiss the New Jersey action and to consolidate the New Jersey and Florida actions.

On February 20, 2008, Sepracor Inc. and University of Massachusetts (“Sepracor”) filed an action in the United States District Court for the District of New Jersey, against Belcher Pharmaceuticals, Inc. and GeoPharma, Inc. alleging that the filing of Belcher Pharmaceuticals’ ANDA for 5 mg Desloratadine Tablets, AB-rated to Clarinex ^® , infringed U.S. Patent No. 7,214,683 (“the ‘683 patent”) and U.S. Patent No. 7,214,684 (“the ‘684 patent”) Case No. 3:08-cv-00945-MLC-TJB.

The Company had earlier filed a Paragraph IV certification to, among other, U.S. Patent Nos. 6,100,274, 7,214,683 and 7,214,684, contesting that these patents were either invalid or had not been infringed upon, which resulted in the subsequent litigation by Schering and Sepracor.

On January 15, 2009, the Company and Belcher reached an agreement with Schering and Sepracor settling all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg), with the Company receiving a license under all relevant parents.

Under the terms of the settlement, the Company can commercially launch its generic Desloratadine product, with 6 month marketing co-exclusivity, on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. The Company’s product is pending FDA approval and seeks an AB-rating as equivalent to Schering’s Clarinex ^® tablets indicated for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis.

During September 2006, the Company, through its 51% owned subsidiary, American Antibiotics, LLC, filed in the Circuit Court for Anne Arundel County, Maryland, Case No. C-06-117230, naming defendents Consolidated Pharmaceutical Group (“CPG”), the directors of CPG and two other individuals acting on behalf of CPG (collectively “the Defendents”). The litigation arises from and relates to agreements entered into between American Antibiotics and CPG for the purchase by American Antibiotics all of CPG’s rights, title and interest in various pharmaceutical Abbreviated New Drug Applications (“ANDAs”) and for the Baltimore Maryland facility lease (the “Lease”). The Suit brought by the Company alleges that the Defendents breached the ANDA agreement with certain misrepresentations and by failing to perform all the required improvements and modifications to the Baltimore, Maryland facility. Consolidated with American Antibiotic’s lawsuit is a separate action file against it by CPG, alleging that American Antibiotics has failed to pay rent that is due and owing under the Lease. Both cases have been stayed pending the outcome of settlement discussions, which are ongoing between the parties.

On May 1, 2006 Esther Krausz and Sharei Yeshua (“Note Holders”) filed an action against Dynamic Health Products, Inc. in the Circuit Court of Broward County, Florida (Index No. 06-6187) alleging Dynamic Health Products, Inc. defaulted on note payment obligations. The face amount of the note alleged to be held by Ester Krausz totals $280,000, the face amount of the note alleged to be held by Sharei Yeshua totals $220,000. The notes contain an interest rate of 8% per annum. Preliminary discovery has been conducted. Dynamic Health Products, Inc. filed a third party action against the agent for the Note Holders seeking indemnity and that action was settled in May 2008. The Note Holders have filed a request for trial with the court but no date has been set. Dynamic Health Products, Inc. is investigating whether the purported agent made any payments to the Note Holders on behalf of Dynamic Health Products, Inc. without disclosing those payments. To date, Plaintiffs have not provided copies of the notes to Dynamic Health Products, Inc. or made a specific monetary demand. Dynamic Health Products, Inc. intends to vigorously defend itself in this action.

From time to time the Company is subject to litigation incidental to its business including possible product liability claims. Such claims, if successful, could exceed applicable insurance coverage.

The Company is, from time to time, involved in litigation relating to claims arising out of its operations in the ordinary course of business. The Company believes that none of the claims that were outstanding as of December 31, 2008 and March 31, 2008 should have a material adverse impact on its financial condition or results of operations.

NOTE 16 – SUBSEQUENT EVENTS

On January 15, 2009, the Company and Belcher reached an agreement with Schering and Sepracor settling all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg), with the Company receiving a license under all relevant parents.

Under the terms of the settlement, the Company can commercially launch its generic Desloratadine product, with 6 month marketing co-exclusivity, on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. The Company’s product is pending FDA approval and seeks an AB-rating as equivalent to Schering’s Clarinex ^® tablets indicated for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis.

On January 26, 2009, the Company entered into an agreement with Trident Biotech, Inc. (“Trident”), an unrelated third party. Under the terms of the agreement, Trident will purchase a majority stake in the Company’s Ovarian Cancer business for a total of $2.5 million in cash and note. The Company will maintain a forty percent ownership in the business.

The Company is in default on its outstanding obligations to Wachovia under the revolving Note and the Term Note (see Note 8 and Note 9). The notes have not been satisfied since their maturity on December 31, 2008. On January 28, 2009, a Judgment By Confession was entered in favor of Wachovia and against the Company, to compel the Company to satisfy its obligations to Wachovia under the notes, in the amount of $2,753,361, including principal and unpaid interest as of January 21, 2009, damages, costs and attorneys’ fees. The Company is seeking to refinance these obligations with other potential lenders, however there can be no assurance that the Company will be able to obtain alternative financing on terms acceptable to it or at all, particularly in light of the current economic and financial market environment, in which event the Company will need to consider all available alternatives.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The statements contained in this Report that are not historical are forward-looking statements, including statements regarding the Company’s expectations, intentions, beliefs or strategies regarding the future. Forward-looking statements include the Company’s statements regarding liquidity, anticipated cash needs and availability and anticipated expense levels. All forward-looking statements included in this Report are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statement. It is important to note that the Company’s actual results could differ materially from those in such forward-looking statements. Additionally, the following discussion and analysis should be read in conjunction with the Financial Statements and notes thereto appearing elsewhere in this Report. The discussion is based upon such financial statements which have been prepared in accordance with U.S. Generally Accepted Accounting Principles and the Standards of the Public Company Accounting Oversight Board (United States).

Management’s Discussion and Analysis of Financial Condition and Results of Operations

We derive our revenues from developing, manufacturing and distributing a wide variety of nutraceuticals and cosmeticeuticals, sports nutrition products, pharmaceutical and generic drugs, and prescription and non-prescription products. We also derive revenues from the distribution of our branded product lines as well as from distributing others’ product lines.

Cost of goods sold is comprised of direct manufacturing and manufacturing and distribution material product costs, direct personnel compensation and other statutory benefits and indirect costs relating to labor to support product manufacture, distribution and the warehousing of production and other manufacturing overhead. In addition, for the distribution segment, the cost of all free goods for the purpose of product introduction or other incentive-based product costs are also recorded.

Research and development expenses that benefit us and that benefit our customers are charged against either cost of goods sold or included within selling, general and administrative expenses as incurred dependent upon whether the R&D relates to direct product materials expended, direct laboratory and manufacturing production costs or whether it relates to indirect or more facility and administrative type costs representing indirect salaries.

Selling, general and administrative expenses include management and general office salaries, taxes and benefits, advertising and promotional expenses, depreciation and amortization, stock compensation, insurance expenses, rents, legal and accounting costs, sales and marketing and other indirect operating costs.

Interest expense, net, consists of interest expense associated with credit lines, convertible debt, borrowings to finance capital equipment expenditures and other working capital needs and is partially offset by interest income earned on our funds held at banks. For the three and nine months ended December 31, 2008 and 2007, interest expense, net, was further reduced by interest expense incurred that was capitalizable based on pharmaceutical leasehold construction projects in process.

Effective May 15, 2007, we discontinued our pharmacy benefit management operations, due to our mutual termination of our PBM contract with Amerigroup, formerly known as CarePlus Health. Therefore, after the contract termination date, we have not received or recorded PBM segment revenues or incurred or recorded related PBM contract expenses. We did not incur contract termination or any related exit costs associated with this contract termination.

For the three and nine months ended December 31, 2007, the following amounts, which are included in our consolidated statement of operations for the three and nine months ended December 31, 2007, as discontinued operations, were attributable to our PBM segment:

• PBM segment revenue of approximately $2.9 million;

• PBM segment gross profit of approximately $20,900;

• PBM segment selling, general and administrative expenses of approximately $20,800; and

• PBM segment exit income of approximately $8,300.

Effective October 16, 2007, we acquired 100% of the common stock of BOSS, a Florida corporation. BOSS develops, markets and distributes a wide variety of sports nutrition products, performance drinks, non-prescription dietary supplements, health and beauty care products, health food and nutritional products, soft goods and other related products. The transaction was accounted for as a purchase. The results of operations of BOSS and its subsidiaries have been included in our results of operations in our statement of operations, since the effective date of acquisition, October 16, 2007, as part of our distribution segment.

The unaudited pro forma effect of the acquisition of BOSS on our revenues, net income (loss) and net income (loss) per share, had the acquisition occurred on April 1, 2007, is as follows:

	Three Months Ended December 31, 2007			Nine Months Ended December 31, 2007
Revenues	$	20,926,244		$	62,955,040
Net income (loss)	$	(1,569,281	)	$	(5,367,176	)
Basic income (loss) per share	$	(0.11	)	$	(0.39	)
Diluted income (loss) per share	$	(0.11	)	$	(0.39	)

The following amounts, which are included in our consolidated statement of operations for the three months ended December 31, 2008, were attributable to BOSS:

• Distribution revenue of approximately $8 million;

• Distribution gross profit of approximately $1.3 million;

• Selling, general and administrative expenses of approximately $1.8 million;

• Depreciation and amortization expense of approximately $48,300;

• Interest income (expense), net of approximately $(36,100); and

• Other income (expense), net of approximately $(12,600).

The following amounts, which are included in our consolidated statement of operations for the nine months ended December 31, 2008, were attributable to BOSS:

• Distribution revenue of approximately $30.7 million;

• Distribution gross profit of approximately $5.3 million;

• Selling, general and administrative expenses of approximately $5.9 million;

• Depreciation and amortization expense of approximately $141,800;

• Interest income (expense), net of approximately $(99,600); and

• Other income (expense), net of approximately $(1,200).

The impact of the results of operations of BOSS on our consolidated net loss for the three and nine months ended December 31, 2008 was net income (loss) of approximately $(579,400) and $(868,000), respectively. See Strategic and Other Activities below.

Results of Operations

The table and the comparative analysis below for results of operations of the three and nine months ended December 31, 2008, as compared to the three and nine months ended December 31, 2007, excludes (1) the results of operations of BOSS, acquired by us effective October 16, 2007 and (2) the results of operations of our discontinued operations, the PBM segment, effective May 15, 2007.

The following table sets forth selected unaudited consolidated statements of operations data as a percentage of revenues for the periods indicated.

	Three Months Ended December 31,				Nine Months Ended December 31,
	2008		2007		2008		2007
Revenues	100.0	%	100.0	%	100.0	%	100.0	%
Cost of goods sold (excluding depreciation and amortization)	82.0	%	77.1	%	81.4	%	78.1	%
Gross profit	18.0	%	22.9	%	18.6	%	21.9	%
Depreciation and amortization	13.4	%	5.6	%	10.7	%	6.1	%
Stock compensation expense	7.2	%	3.3	%	5.6	%	3.3	%
Selling, general and administrative expenses	67.4	%	41.3	%	59.8	%	46.1	%
Other income (expense), net	(9.5	)%	(2.3	)%	(7.5	)%	(1.2	)%
Income (loss) before minority interest, income taxes and preferred dividends	(79.5	)%	(29.7	)%	(65.1	)%	(34.8	)%
Minority interest benefit	3.0	%	2.5	%	2.8	%	3.1	%
Income tax benefit (expense)	3.1	%	9.2	%	9.6	%	11.6	%
Preferred stock dividends	2.7	%	1.3	%	2.3	%	1.5	%
Net income (loss)	(76.1	)%	(19.3	)%	(55.0	)%	(21.6	)%

Three Months Ended December 31, 2008, Compared to Three Months Ended December 31, 2007

Our analysis of the three months ended December 31, 2008, as compared to the three months ended December 31, 2007, excludes the results of operations of BOSS, acquired October 16, 2007, and our PBM segment, discontinued on May 15, 2007.

Revenues

Our total revenues decreased approximately $2.9 million, or 36.2%, to approximately $5.1 million for the three months ended December 31, 2008, from approximately $8 million for the three months ended December 31, 2007.

Manufacturing revenues decreased approximately $2.9 million, or 41.8%, to approximately $4.1 million for the three months ended December 31, 2008, as compared to approximately $7 million for the three months ended December 31, 2007. During the three months ended December 31, 2008, we experienced a decrease in sales volume driven by the significant weakening of demand for the products that we manufacture for our customers, due to the global economic downturn, which has negatively impacted end user demand for the products we produce. Manufacturing capacities and capabilities continue to be increased as we continue to enhance our existing core manufacturing equipment and standard operating procedures. We believe the reduction in demand for the products we produce could continue for some time. Consequently, based on continued economic uncertainty, we believe it is likely that our manufacturing revenues may decline further in the near future.

Distribution revenues decreased approximately $447,400, or 47.3%, to approximately $498,900 for the three months ended December 31, 2008, as compared to approximately $946,300 for the three months ended December 31, 2007. For the three months ended December 31, 2008, 370 cases of Hoodia DEX-L10 were sold versus 1,747 cases sold for the three months ended December 31, 2007. In addition, during March 2007, we had introduced a new product line DEX-C20, of which 2,232 cases were sold during the three months ended December 31, 2008. Overall, sales prices vary for all product lines and are dependent upon a customer’s individual as well as aggregate purchase volumes in addition to the number of distribution points of sale and advertising dollars projected to be spent. During the three months ended December 31, 2008, we experienced a decrease in sales volume for the products we distribute, driven by increased competition at the mass retail chain level where the majority of the products are sold, as well as a significant weakening of demand for our products, due to the global economic downturn, which has negatively impacted end user demand for the products we distribute. We believe the reduction in demand for the products we distribute could continue for some time. Consequently, based on continued economic uncertainty, we believe it is likely that our distribution revenues may decline further in the near future.

Pharmaceutical revenues were approximately $504,000 for the three months ended December 31, 2008. There were no sales for this business segment for the three months ended December 31, 2007. During the three months ended December 31, 2008, pharmaceutical revenues were comprised of sales of Vetprofen ™ , the Company’s brand of Carprofen, which was approved by the FDA during November 2007. Our Carprofen is sold in three different strengths: 25 mg, 75 mg and 100 mg. Of the total pharmaceutical revenues for the three months ended December 31, 2008, sales were comprised of 713 cases of 75 mg and 837 cases of 100 mg of Carprofen.

Gross Profit

Our total gross profit decreased approximately $904,900 or 49.7%, to approximately $915,300 for the three months ended December 31, 2008, as compared to approximately $1.8 million for the three months ended December 31, 2007. Total gross margins decreased to 18% for the three months ended December 31, 2008 from 22.9% for the three months ended December 31, 2007.

Manufacturing gross profit decreased approximately $1 million, or 45.4%, to approximately $1.2 million for the three months ended December 31, 2008, as compared to approximately $2.2 million for the three months ended December 31, 2007. For the three months ended December 31, 2008 manufacturing gross margin decreased to 29.8%, from 31.8% for the three months ended December 31, 2007. Gross profit and gross margin have declined based on lower utilization of our manufacturing capacity with the lower level of our sales volume, as well as higher costs with increases in freight charges due to increased fuel costs, increases in resin and plastic-based packaging component costs, as well as increased labor costs. Current increases in this type of labor-based direct overhead costs are in line with our planned improvements surrounding enhanced standard operating and manufacturing procedures in all of our manufacturing plants. We expect that these improvements will continue to increase our visibility in the marketplaces that we compete in for new and expanded business for the upcoming fiscal year.

Distribution gross profits decreased approximately $278,500, or 66.3%, to approximately $141,700 for the three months ended December 31, 2008, as compared to approximately $420,200 for the three months ended December 31, 2007. Distribution gross margins decreased to 28.4% for the three months ended December 31, 2008, as compared to 44.4% for the three months ended December 31, 2007. Gross profits and gross margins have declined based on the lower level of our sales volume and increased competition, which caused additional short-term price concessions and a change in the chain store sales mix. In addition, gross margins can vary in a given quarter based on sales promotions and advertising efforts.

Pharmaceutical gross profits increased approximately $385,900, or 46.6%, to a gross profit deficit of approximately $442,900 for the three months ended December 31, 2008, as compared to approximately $828,700 in gross profit deficit for this business segment for the three months ended December 31, 2007. This was based primarily on the Cephalasporin and Beta-Lactam facilities that have no revenue streams but have costs associated with overall research and product development, and production and laboratory direct labor costs. The Largo, Florida generic drug plant has commenced initial manufacturing and began shipping Vetprofen ™ , its branded generic Carprofen, during the fourth fiscal quarter ended March 31, 2008, which has assisted in offsetting some of the costs associated with other research and product development, production and laboratory direct costs related to the pharmaceutical segment. The Largo, Florida Cephalasporin and generic drug plants incurred approximately $841,000 of costs with the Baltimore, Maryland Beta-Lactam facility having incurred approximately $106,000 of costs with revenue offsets of approximately $504,000. The drug revenues derived were generated from our generic drug plant in Largo, Florida. We are awaiting FDA facility approval of both the Baltimore, Maryland Beta-Lactam and the Largo, Florida Cephalosporin drug facility plants and we estimate and anticipate that we will begin to derive revenues during the fourth quarter of the fiscal year ending March 31, 2009 or the first quarter of the fiscal year ending March 31, 2010.

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses consist of advertising and promotional expenses; stock compensation costs, insurance costs, research and development costs associated with the generic drug segment, personnel costs related to general management functions, finance, accounting and information systems, payroll expenses and sales commissions; professional fees related to legal, audit and tax matters; and depreciation and amortization expenses. Selling, general and administrative expenses, inclusive of stock compensation and depreciation and amortization expenses, increased approximately $471,300, or 11.8%, to approximately $4.5 million for the three months ended December 31, 2008, as compared to approximately $4 million for the three months ended December 31, 2007. An increase of approximately $134,000 was due to the increase in amortizable intangible assets related to our distribution segment; approximately $98,000 was due to the increase in purchased depreciable assets related to generic drug, cosmeceutical and nutraceutical manufacturing; approximately $222,000 increase in legal; approximately $101,000 increase in the stock compensation expense directly related to the issuance of 3-year restricted stock awards; approximately $52,000 increase in consulting fees; and approximately $374,000 increase in bad debt expense; all of which were partially offset by a decrease of approximately $391,000 in advertising and promotional expenses associated with promoting our distribution segment and related branded product lines; a decrease of approximately $56,000 in filing fees; a decrease of approximately $52,000 in repair and maintenance; and a decrease of approximately $40,000 increase in travel related expenses. As a percentage of sales, selling, general and administrative expenses increased to 88% for the three months ended December 31, 2008, from 50.3% for the three months ended December 31, 2007. We have instituted material cost reduction initiatives commencing in December 2008 and expect to begin experiencing the benefits of such initiatives commencing in our fourth fiscal quarter ended March 31, 2009. See Strategic and Other Activities below.

Operating Income (Loss)

Operating loss was approximately $3.6 million, or 70% of revenues for the three months ended December 31, 2008, compared to an operating loss of approximately $2.2 million, or 27.4% of revenues for the three months ended December 31, 2007. Although we have instituted cost reduction initiatives, the continued economic uncertainty and potential further decline in our revenues could cause us to operate in an operating loss position in the near future.

Other Income (Expense), Net

Other income (expense), net was approximately $(482,200) for the three months ended December 31, 2008, compared to approximately $(184,900) for the three months ended December 31, 2007. Interest income (expense), net, was approximately $(501,100) for the three months ended December 31, 2008, compared to approximately $(184,900) for the three months ended December 31, 2007. The increase in interest expense was primarily attributable to interest expense associated with our convertible debt in addition to our short-term obligations issued during fiscal 2008, and was partially offset by interest capitalized on our generic pharmaceutical leasehold construction. For the three months ended December 31, 2008, other income (expense), net, of approximately $18,900, primarily consisted of allowances on prior year vendor balances. For the three months ended December 31, 2007, other income (expense), net, was zero.

Income Tax Benefit (Expense)

For the three months ended December 31, 2008, we had recorded approximately $158,300 of income tax benefit as compared to approximately $730,000 of income tax benefit for the three months ended December 31, 2007. The tax benefit was based on our tax calculation of temporary and permanent differences using the effective tax rates applied to our net loss for the period, changes in information gained related to underlying assumptions about our future operations, as well as the utilization of available operating loss carryforwards. In accordance with SFAS No. 109, “Accounting for Income Taxes,” we have evaluated whether it is more likely than not that the deferred tax asset will be realized. Based on available evidence, we have concluded that it is more likely than not that the increase in the asset will be realized by carrying back approximately $3.5 million of the operating loss and by carrying forward the remainder of the loss to future periods through the expiration dates of the operating loss carryforwards beginning 2021 and ending 2028.

Nine Months Ended December 31, 2008, Compared to Nine Months Ended December 31, 2007

Our analysis of the nine months ended December 31, 2008, as compared to the nine months ended December 31, 2007, excludes the results of operations of BOSS, acquired October 16, 2007, and our PBM segment, discontinued on May 15, 2007.

Revenues

Our total revenues decreased approximately $2.3 million, or 11%, to approximately $18.5 million for the nine months ended December 31, 2008, from approximately $20.8 million for the nine months ended December 31, 2007.

Manufacturing revenues decreased approximately $1.7 million, or 10.3%, to approximately $14.9 million for the nine months ended December 31, 2008, as compared to approximately $16.6 million for the nine months ended December 31, 2007. During the nine months ended December 31, 2008, we experienced a decrease in sales volume driven by the significant weakening of demand for the products that we manufacture for our customers, due to the global economic downturn which has negatively impacted end user demand for the products we produce. Manufacturing capacities and capabilities continue to be increased as we continue to enhance our existing core manufacturing equipment and standard operating procedures. We believe the reduction in demand for the products we produce could continue for some time. Consequently, based on continued economic uncertainly, we believe it is likely that our manufacturing revenues may decline further in the near future.

Distribution revenues decreased approximately $1.7 million, or 41%, to approximately $2.5 million for the nine months ended December 31, 2008, as compared to approximately $4.2 million for the nine months ended December 31, 2007. For the nine months ended December 31, 2008, 4,891 cases of Hoodia DEX-L10 were sold versus 6,819 cases sold for the nine months ended December 31, 2007. In addition, during March 2007, we had introduced a new product line DEX-C20, of which 14,296 cases were sold during the nine months ended December 31, 2008. Overall, sales prices vary for all product lines and are dependent upon a customer’s individual as well as aggregate purchase volumes in addition to the number of distribution points of sale and advertising dollars projected to be spent. During the nine months ended December 31, 2008, we experienced a decrease in overall distribution sales volume, driven by increased competition at the mass retail chain level where the majority of the products are sold, as well as a significant weakening of demand for our products, due to the global economic downturn, which has negatively impacted end user demand for the products we distribute. We believe the reduction in demand for the products we distribute could continue for some time. Consequently, based on continued economic uncertainty, we believe it is likely that our distribution revenues may decline further in the near future.

Pharmaceutical revenues increased approximately $1.1 million, or 2,722.2%, to approximately $1.2 million for the nine months ended December 31, 2008, as compared to approximately $41,200 in sales for this business segment for the nine months ended December 31, 2007. During the nine months ended December 31, 2008, pharmaceutical revenues were comprised of sales of Vetprofen ™ , the Company’s brand of Carprofen, which was approved by the FDA during November 2007. Our Carprofen is sold in three different strengths: 25 mg, 75 mg and 100 mg. Of the total pharmaceutical revenues for the nine months ended December 31, 2008, sales were comprised of 415 cases of 25 mg, 1,538 cases of 75 mg and 1,660 cases of 100 mg of Carprofen.

Gross Profit

Our total gross profit decreased approximately $1.1 million or 24.6%, to approximately $3.4 million for the nine months ended December 31, 2008, as compared to approximately $4.6 million for the nine months ended December 31, 2007. Total gross margins decreased to 18.6% for the nine months ended December 31, 2008 from 21.9% for the nine months ended December 31, 2007.

Manufacturing gross profit decreased approximately $659,900, or 13.1%, to approximately $4.4 million for the nine months ended December 31, 2008, as compared to approximately $5 million for the nine months ended December 31, 2007. For the nine months ended December 31, 2008 manufacturing gross margin decreased to 29.3%, from 30.3% for the nine months ended December 31, 2007. Gross profit and gross margin have declined based on lower utilization of our manufacturing capacity with the lower level of our sales volume, as well as higher costs with increases in freight charges due to increased fuel costs, increases in resin and plastic-based packaging component costs, as well as increased labor costs. Current increases in this type of labor-based direct overhead costs are in line with our planned improvements surrounding enhanced standard operating and manufacturing procedures in all of our manufacturing plants. We expect that these improvements will continue to increase our visibility in the marketplaces that we compete in for new and expanded business for the upcoming fiscal year.

Distribution gross profits decreased approximately $923,700, or 48.6%, to approximately $976,300 for the nine months ended December 31, 2008, as compared to approximately $1.9 million for the nine months ended December 31, 2007. Distribution gross margins decreased to 39.7% for the nine months ended December 31, 2008, as compared to 45.6% for the nine months ended December 31, 2007. Gross profits and gross margins have declined based on the lower level of our sales volume and increased competition, which caused additional short-term price concessions and a change in the chain store sales mix. In addition, gross margins can vary in a given quarter based on sales promotions and advertising efforts.

Pharmaceutical gross profits increased approximately $463,000, or 19.6%, to a gross profit deficit of approximately $1.9 million for the nine months ended December 31, 2008, as compared to approximately $2.4 million in gross profit deficit for this business segment for the nine months ended December 31, 2007. This was based primarily on the Cephalasporin and Beta-Lactam facilities that have no revenue streams but have costs associated with overall research and product development, and production and laboratory direct labor costs. The Largo, Florida generic drug plant has commenced initial manufacturing and began shipping Vetprofen ™ , its branded generic Carprofen, during the fourth fiscal quarter ended March 31, 2008, which has assisted in offsetting some of the costs associated with other research and product development, production and laboratory direct costs related to the pharmaceutical segment. The Largo, Florida Cephalasporin and generic drug plants incurred approximately $2.7 million of costs with the Baltimore, Maryland Beta-Lactam facility having incurred approximately $392,000 of costs with revenue offsets of approximately $1.2 million. The drug revenues derived were generated from our generic drug plant in Largo, Florida. We are awaiting FDA facility approval of both the Baltimore, Maryland Beta-Lactam and the Largo, Florida Cephalosporin drug facility plants and we estimate and anticipate that we will begin to derive revenues during the fourth quarter of the fiscal year ending March 31, 2009 or the first quarter of the fiscal year ending March 31, 2010.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist of advertising and promotional expenses; stock compensation costs, insurance costs, research and development costs associated with the generic drug segment, personnel costs related to general management functions, finance, accounting and information systems, payroll expenses and sales commissions; professional fees related to legal, audit and tax matters; and depreciation and amortization expenses. Selling, general and administrative expenses, inclusive of stock compensation and depreciation and amortization expenses, increased approximately $2.6 million, or 22.1%, to approximately $14.1 million for the nine months ended December 31, 2008, as compared to approximately $11.6 million for the nine months ended December 31, 2007. An increase of approximately $382,000 was due to the increase in amortizable intangible assets related to our distribution segment; approximately $331,000 was due to the increase in purchased depreciable assets related to generic drug, cosmeceutical and nutraceutical manufacturing; officer and employee salaries have increased approximately $392,000 in total based on increases in the number of personnel in addition to merit increases and bonuses received, and the related increase in payroll taxes was approximately $104,000; approximately $355,000 increase in the stock compensation expense directly related to the issuance of 3-year restricted stock awards; approximately $355,000 increase in legal; approximately $147,000 in increased accounting costs primarily associated with the initial implementation of Sarbanes-Oxley compliance; approximately $139,000 increase in bank and filing fees; approximately $103,000 increase in utilities; approximately $84,000 increase in consulting fees; approximately $384,000 increase in bad debt expense; and approximately $44,000 increase in licenses and permits; all of which were partially offset by a decrease of approximately $97,000 in insurance costs; a decrease of approximately $70,000 in director fees; a decrease of approximately $55,000 in credit card processing fees; and a decrease of approximately $46,000 in convention and seminar costs. As a percentage of sales, selling, general and administrative expenses increased to 76.2% for the nine months ended December 31, 2008, from 55.5% for the nine months ended December 31, 2007. We have instituted material cost reduction initiatives commencing in December 2008 and expect to begin experiencing the benefits of such initiatives commencing in our fourth fiscal quarter ended March 31, 2009. See Strategic and Other Activities below.

Operating Income (Loss)

Operating loss was approximately $10.7 million, or 57.6% of revenues for the nine months ended December 31, 2008, compared to an operating loss of approximately $7 million, or 33.6% of revenues for the nine months ended December 31, 2007. Although we have instituted cost reduction initiatives, the continued economic uncertainty and potential further decline in our revenues could cause us to operate in an operating loss position in the near future.

Other Income (Expense), Net

Other income (expense), net was approximately $(1.4) million for the nine months ended December 31, 2008, compared to approximately $(257,400) for the nine months ended December 31, 2007. Interest income (expense), net, was approximately $(1.4) million for the nine months ended December 31, 2008, compared to approximately $(257,900) for the nine months ended December 31, 2007. The increase in interest expense was primarily attributable to interest expense associated with our convertible debt in addition to our short-term obligations issued during fiscal 2008, and was partially offset by interest capitalized on our generic pharmaceutical leasehold construction. For the nine months ended December 31, 2008, other income (expense), net, of approximately $21,400, primarily consisted of allowances on prior year vendor balances. For the nine months ended December 31, 2007, other income (expense), net, of approximately $500, primarily consisted of recycling income.

Income Tax Benefit (Expense)

For the nine months ended December 31, 2008, we had recorded approximately $1.8 million of income tax benefit as compared to approximately $2.4 million of income tax benefit for the nine months ended December 31, 2007. The tax benefit was based on our tax calculation of temporary and permanent differences using the effective tax rates applied to our net loss for the period, changes in information gained related to underlying assumptions about our future operations, as well as the utilization of available operating loss carryforwards. In accordance with SFAS No. 109, “Accounting for Income Taxes,” we have evaluated whether it is more likely than not that the deferred tax asset will be realized. Based on available evidence, we have concluded that it is more likely than not that the increase in the asset will be realized by carrying back approximately $3.5 million of the operating loss and by carrying forward the remainder of the loss to future periods through the expiration dates of the operating loss carryforwards beginning 2021 and ending 2028.

Inflation and Seasonality

We believe that there was no material effect on our operations or our financial condition as a result of inflation as of and for the three and nine months ended December 31, 2008 and 2007. We also believe that our business is not seasonal, however significant promotional activities can have a direct impact on our sales volume in any given quarter.

Economic and Industry Conditions

We believe the global economy is in recession and we first began to see significant adverse effects of this during our quarter ended December 31, 2008, as there was a significant reduction in end user demand for the products we manufacture and distribute, primarily based on the decline of end user discretionary income available for spending. We believe our financial results for the quarter ended December 31, 2008 reflect the continuation and acceleration of a softening of demand for our products driven by the global economic downturn. We believe the decline in our revenues generally was consistent with the decrease in overall industry demand. We believe that the significant decline in economic and industry conditions has had a negative effect, that we are unable to quantify, on our operations and our financial condition as of and for the three and nine months ended December 31, 2008. There are many factors that make it difficult for us to predict future revenue trends for our business, including the duration of the global economic downturn and quarter to quarter changes in customer orders regardless of industry strength. Should there be a continued material deterioration of economic or industry conditions, our results of operations could further be impacted in any given quarter.

Strategic and Other Activities

To address the impact of the economic downturn on our business, commencing in December 2008, we have taken actions intended to improve and optimize our operating effectiveness and to reduce our costs.

We renegotiated our national freight contract which encompasses freight-in and freight-out at all levels of delivery for each of our segments. We have also reduced annual, merit-based salary increases, and taken other steps to reduce or eliminate certain discretionary expenses, including reducing our workforce. These actions, together with those indicated below, are intended to improve our operating effectiveness during the current economic downturn. We are prepared to take additional actions as needed if this soft economic environment continues or worsens.

For our manufacturing segment, we have shortened work schedules to reduce overtime costs and staggered working hours to more closely match production of our products with demand from our customers. With this approach, we retain the flexibility to ramp our production up or down to meet customer demand while managing our production costs. In addition, we have instituted certain other cost reduction initiatives. Since we believe the skills and expertise of our employees are key to our Company’s success, our initial cost management actions have been directed at minimizing expenses without incurring an extensive workforce reduction, but we are prepared to take more severe actions in the future if appropriate.

For our distribution segment, we have lowered our prices to be more competitive, yet are not experiencing any decrease in our product costs. We are working on changing vendor imposed purchasing requirements, as well as obtaining additional financing so that we may be able to once again take advantage of discounts related to mass volume purchases, resulting in cost savings. We are also working with our vendors to improve our product mix by obtaining products that are in greater demand by our customers.

During December 2008 and January 2009, we closed two of BOSS’s distribution facilities, the Rhode Island and Texas locations, thereby consolidating distribution facilities, resulting in transparent transition to our customers, as those customers are now being serviced through our Pennsylvania, Nevada and Florida locations. We expect this to result in substantial decreases in SG&A expenses in the foreseeable future, estimated to be in excess of $100,000 per quarter, commencing with our fourth fiscal quarter ended March 31, 2009. Although anticipated, some of the cost savings may not be realized in the near future.

Financial Condition, Liquidity and Capital Resources

We had approximately $324,700 of cash and cash equivalents as of December 31, 2008, a decrease from approximately $523,800 as of March 31, 2008. We had a working capital deficit of approximately $3.8 million as of December 31, 2008, inclusive of current portion of long-term obligations. As of March 31, 2008, we had working capital of approximately $1.2 million, inclusive of current portion of long-term obligations. As of December 31, 2008 and March 31, 2008, our liquidity is affected by our certificates of deposit of approximately $5 million and $6 million, respectively, which is included in current assets and which is pledged as collateral for our short-term obligation to First Community Bank of America.

We have financed our operations and growth primarily through cash flows operations, borrowing under our revolving credit facility, operating leases, trade payables, the issuance of short-term obligations, and the receipt of $15 million of gross private placement proceeds based on our April 2007 $10 million 6% convertible preferred stock private placement together with $2.5 million issuance of common stock and a March 2004 $5 million convertible preferred stock.

On April 5, 2007, we closed on $12.5 million financing with Whitebox Pharmaceutical Growth Fund, Ltd. (“Whitebox”), comprised of 8%, 6 year Convertible Debt together with $2.5 million of our $0.01 par value common stock together with 400,000 warrants as related to the $2.5 million in common stock. The $10 million of debt is convertible into our common stock at $4.36 with the 400,000 warrants convertible into our common stock at $5.23.

The Company and Whitebox entered into two registration rights agreements dated April 5, 2007, one related to 573,395 shares of common stock of the Company owned by Whitebox and the other related to the shares of common stock of the Company issuable upon conversion, or as payment of interest and principal with regard to, the $10,000,000 8% Secured Convertible Promissory Note dated April 5, 2007. In compliance with the foregoing, the Company filed a registration statement (file no. 333-142369) with the Securities and Exchange Commission (the “SEC”) and caused it to become effective on December 7, 2007, pursuant to which the Company registered 1,931,395 shares, consisting of the 573,395 shares owned by Whitebox, up to 1,214,597 shares issuable upon the conversion of the note, up to 143,403 shares issuable upon the exercise of warrants owned by Rodman & Renshaw.

On April 24, 2008, the Company and Whitebox Pharmaceutical Growth Fund, Ltd. (“Whitebox”) entered into an Amended and Restated Note Purchase Agreement (the “Restated Note Purchase Agreement”), Amended and Restated Convertible Promissory Note (the “Restated Note”), and Amended and Restated Registration Rights Agreement (the “Restated Registration Rights Agreement” and collectively with the “Restated Note Purchase Agreement and “Restated Note,” the “Restated Agreements”), all of which collectively serve to amend and restate the Original Note, Original Note Purchase Agreement and the Original Registration Rights Agreements. The material amendments contained in the Restated Agreements include the following:

• The Additional Notes contemplated by the Original Note Purchase Agreement have been eliminated and replaced by adding the principal amount of the Additional Notes ($5,000,000) to the Restated Note, thus increasing the total principal amount of the Restated Note to $15,000,000.

• The terms and conditions necessary to satisfy the issuance of the Subsequent Notes contemplated by the Original Note Purchase Agreement have been modified so that Whitebox is now required to make such loan upon the Company’s acquisition of the real estate related to its Beta-Lactam facility (which it currently leases) in Baltimore, Maryland and the satisfaction or waiver of certain other closing conditions related thereto.

• All interest that had accrued on the Original Note from its original issue date (April 5, 2007) through April 24, 2008, in the amount of $865,058, has been converted by Whitebox into a total of 389,666 shares of the Company’s Common Stock in full satisfaction of such accrued interest.

• The interest rate on the Restated Note from and after April 24, 2008 has been increased to 12%, but all of such interest may now be paid, at the option of the Company in shares of common stock of the Company valued at 95% of the volume weighted average market price of the shares during the 5 trading days immediately preceding the payment of interest, provided that certain “Equity Conditions” (as defined in the Restated Note) have been satisfied. If the Company does not meet the Equity Conditions, and if funds are legally available for the payment of interest, then the Company must pay such interest in cash.

• All requirements that the Company meet certain minimum EBITDA targets have been deleted and replaced by a requirement that the Company’s Current Assets (defined as the sum of (w) 100% of the Company’s cash, plus (x) 100% of the Company’s net accounts receivables plus (y) 50% of the Company’s net inventory plus (z) 30% of the Company’s net property, plant and equipment) exceeds the Company’s Total Debt (defined as indebtedness of the Company and its subsidiaries (x) to Whitebox, (y) under the $4,000,000 revolving promissory note with Wachovia Bank, National Association and (z) under the $5,000,000 promissory note with First Community Bank of America.) If the Company fails to satisfy the foregoing Current Assets Test as of

the required date for filing any Form 10-K or Form 10-Q, as applicable (the “Current Assets Test Measurement Date”), Whitebox may require the Company to redeem up to $2,000,000 of the principal amount of the Restated Note as of such Current Assets Test Measurement Date. In addition, if the Company’s Total Debt exceeds the Company’s Current Assets by more than $2,000,000 as of the Current Assets Test Measurement Date, such shortfall will constitute an Event of Default under the Restated Note, in which case the entire outstanding principal amount (including any Accreted Principal or Make-Whole Amounts (as defined by the Restated Note)) under the Restated Note will be due and payable on the 30 ^th day after the occurrence of such default if the Company is unable to cure such default within such thirty (30) day period. The Company is in default of the Current Asset Test requirement as of December 31, 2008.

• The provision of the Original Note Purchase Agreement that allowed Whitebox to put 1/10th of the outstanding principal amount of the Original Note (including any accreted interest) to the Company at par if (A) the sum of the Company’s (i) net accounts receivable, plus (ii) cash and cash equivalents, plus (iii) marketable securities at the end of any quarterly period were less than $7,000,000, or (B) the Company’s revenues were less than $5,000,000 for the most recently reported quarterly period, has been deleted.

• The Company agreed to register all of the shares issuable pursuant to the Restated Note (whether as a result of a conversion or otherwise) to the extent permitted by the SEC in accordance with its rules and regulations.

• The Company paid to Whitebox a $1,400,000 financing fee in cash.

The offering and sale of the Restated Note (as well as the Original Note and the shares issuable to Whitebox pursuant thereto) were deemed to be exempt under Rule 506 of Regulation D and Section 4(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The offering and sale were made only to one accredited investor, and transfer of the securities has been restricted in accordance with the requirements of the Securities Act of 1933. The Company received written representations from Whitebox regarding, among other things, its accredited-investor status and investment intent.

The Company has received notices from Whitebox alleging two separate defaults under the Restated Note.

The first default letter, dated November 25, 2008, relates to an alleged failure by the Company to use its commercially reasonable efforts to obtain a second priority lien on the assets owned by BOSS, which the Company cannot do without the prior written consent of Wachovia Bank, National Association (“Wachovia”). Wachovia is the primary lender to BOSS. The Company’s obligations to Wachovia matured on December 31, 2008 and are currently in default. Whitebox also takes the position in this letter that as a result of the forgoing alleged default, the Restated Note has been incurring default interest at a rate of 18% since September 20, 2008. Whitebox has since agreed to the interest rate remaining at 12% until March 1, 2009.

The second Whitebox default letter, dated December 5, 2008, relates to an alleged failure by the Company to redeem $2,000,000 of the Restated Note as a result of the Company’s alleged failure to satisfy the Current Asset Test as of September 30, 2008. The Note Purchase Agreement provides that if the Company’s Total Debt exceeds its Current Equity at the end of any fiscal quarter, Whitebox may require the Company to redeem up to $2,000,000 of the principal amount of the Restated Note.

Whitebox could seek repayment, but has given no indication of doing so. The Company is actively involved in negotiations with Whitebox to reach a mutually acceptable arrangement to restructure the financing. There can be no assurance that the Company and Whitebox will reach a mutually acceptable arrangement. If repayment is required, the Company would not have sufficient funds and Whitebox could take legal action to recover amounts due from our assets. Meanwhile, the Company will continue to attempt to reduce expenses and to explore alternate financing arrangements with other potential lenders to refinance all of the Company’s facilities. Again, there can be no assurance that the Company will be able to obtain additional or alternative financing on terms acceptable to it or at all, particularly in light of the current economic and financial market environment, in which event the Company will need to consider all available alternatives.

On October 12, 2007, BOSS issued a revolving Promissory Note (“Note”) to Wachovia, in the amount of $4 million or such sum as may be advanced and outstanding from time to time, pursuant to the Loan Agreement. Interest shall accrue on the unpaid principal balance and varies based on the LIBOR Market Index Rate plus 1.75%, for any day. The note is due and payable in consecutive monthly payments of accrued interest only, commencing on November 20, 2007, and continuing on the same day of each month thereafter until fully paid. In any event, all principal and accrued interest shall be due and payable on August 31, 2008. On March 28, 2008, the Company entered into loan modification agreements with Wachovia, whereby the amount of the October 12, 2007 revolving Note to Wachovia was reduced from $4 million to $2.5 million, or such sum as may be advanced and outstanding from time to time, and $750,000 of the principal balance of the revolving Note was converted to a term Promissory Note (“Term Note”), both maturing on August 31, 2008. In addition, the rate of interest was modified whereby interest shall accrue on the unpaid principal balance and varies based on the LIBOR Market Index Rate plus 3.15%, for any day. Certain terms of the loan were modified including the financial covenant in regards to the liquidity ratio. The Term Note is due and payable in consecutive monthly payments of principal equal to $50,000 plus accrued interest, commencing on May 1, 2008 and continuing on the same day of each month thereafter until fully paid. On April 25, 2008, we entered into a Modification Number 001 To Loan Agreement and a Modification Number 001 To Promissory Note with Wachovia, whereby certain terms of the loan were modified, including the financial covenant in regards to liquidity ratio.

On August 28, 2008, we entered into an Allonge to Promissory Note with Wachovia, with respect to the $2.5 million revolving Note, whereby the rate of interest was modified so that interest shall accrue on the unpaid principal balance and varies based on the Prime Rate plus 2%. “Prime Rate” shall mean the floating annual rate of interest that is designated from time to time by Wachovia as the “Prime Rate” and is used by Wachovia as a reference based with respect to interest rates charged to borrowers. In addition, the maturity date was extended to December 31, 2008. The principal balance was $2,214,000 and $1,856,000, at December 31, 2008 and March 31, 2008, respectively.

In addition, on August 28, 2008, we entered into an Allonge to Promissory Note with Wachovia, with respect to the $750,000 Term Note, whereby the rate of interest was modified so that interest shall accrue on the unpaid principal balance and varies based on the Prime Rate plus 2%. “Prime Rate” shall mean the floating annual rate of interest that is designated from time to time by Wachovia as the “Prime Rate” and is used by Wachovia as a reference based with respect to interest rates charged to borrowers. In addition, the maturity date was extended to December 31, 2008. The principal balance was $400,000 and $750,000, at December 31, 2008 and March 31, 2008, respectively.

The Company is in default on its outstanding obligations to Wachovia under the revolving Note and the Term Note (see Note 8 and Note 9). The notes have not been satisfied since their maturity on December 31, 2008. On January 28, 2009, a Judgment By Confession was entered in favor of Wachovia and against the Company, to compel the Company to satisfy its obligations to Wachovia under the notes, in the amount of $2,753,361, including principal and unpaid interest as of January 21, 2009, damages, costs and attorneys’ fees. The Company is seeking to refinance these obligations with other potential lenders, however there can be no assurance that the Company will be able to obtain alternative financing on terms acceptable to it or at all, particularly in light of the current economic and financial market environment, in which event the Company will need to consider all available alternatives.

On April 6, 2008, we entered into a Change In Terms Agreement with First Community Bank of America (“FCB”), whereby the $3,500,000 promissory note issued to FCB on October 1, 2007 was modified and consolidated with the $500,000 promissory note issued to FCB on December 20, 2007 and the $1,000,000 promissory note issued to FCB on January 18, 2008. In accordance with the modified terms, interest on the note is payable monthly in arrears, commencing May 6, 2008, at the rate of 5.15% per annum, with the entire principal payment of $5,000,000 plus interest being due on October 6, 2008. In connection with the promissory note, we assigned, as collateral security for the note, a certificate of deposit account with FCB in the approximate balance of $6 million as of March 31, 2008, including interest thereon. On October 6, 2008, the Company entered into a Change In Terms Agreement with FCB, whereby the terms of the promissory note were modified so that interest on the note is payable monthly in arrears, commencing November 6, 2008, at the rate of 5.21% per annum, with the entire principal payment of $5,000,000 plus interest being due on October 6, 2009.

On June 18, 2008, the Compensation Committee of the Company’s Board of Directors, with the approval of the Company’s Board of Directors, awarded the Company’s management a total of 1,532,256 shares of 3-year restricted Company common stock pursuant to the 2005-2007 Compensation Incentive Plan. As a result, the Company recorded a deferred compensation asset of approximately $2,221,771, which is being amortized over 36 months to stock compensation expense within selling, general and administrative expenses on the Company’s statements of operations.

In September 2008, Jugal Taneja, the Company’s Chairman of the Board of Directors, loaned the Company $150,000. Interest on the note is at the rate of 7% per annum. The balance of the note, together with accrued interest, is due and payable on or before March 31, 2009. Proceeds were used for working capital.

On September 30, 2008, the Company issued an $800,000 promissory note to First Community Bank of America. The note is payable in six consecutive monthly payments of accrued interest only, commencing on October 30, 2008, and 54 monthly consecutive principal and interest payments of approximately $17,166, commencing April 30, 2009, at the rate of 6.5% per annum. In any event, all principal and accrued interest shall be due and payable on September 30, 2013. The note is secured by equipment as described in a Commercial Security Agreement issued to FCB on September 30, 2008. In addition, Jugal Taneja, the Company’s Chairman of the Board of Directors, assigned, as collateral security for the note, his certificate of deposit account with FCB in the amount of $400,000. Proceeds of the note were used for the purchase of equipment. Future advances under the note are to be used for equipment purchases. The principal balance of the note was $450,829 at December 31, 2008.

On December 8, 2008, a holder of 1,025 shares of Company 6% convertible preferred stock, Series B, $.01 par value, converted such shares into 235,092 shares of Company common stock, at a set conversion price of $4.36 per common share. The closing price of the Company’s common stock was $.40 at the close of business for the Nasdaq Capital Market on December 5, 2008.

NINE MONTH ENDED DECEMBER 31, 2008 CASH FLOW ANALYSIS

The following table summarizes our cash flows from operating, investing and financing activities for each of the nine months ended December 31, 2008 and 2007:

Nine Months Ended December 31,	2008			2007
Total cash provided by (used in):
Operating activities	$	(3,927,540	)	$	(975,677	)
Investing activities	$	(1,589,267	)	$	(12,459,505	)
Financing activities	$	5,317,744		$	13,099,874
Increase (decrease) in cash and cash equivalents	$	(199,063	)	$	(335,308	)

Operating Activities

Net cash used in operating activities was approximately $3.9 million for the nine months ended December 31, 2008, as compared to net cash used in operating activities of approximately $1 million for the nine months ended December 31, 2007. The decline in operating cash flows for the nine months ended December 31, 2008, compared with the nine months ended December 31, 2007, was due primarily to the increase in our net loss.

We incurred a net loss before preferred stock dividends of approximately $10.6 million for the nine months ended December 31, 2008, compared to a net loss before preferred stock dividends of approximately $4.3 million for the nine months ended December 31, 2007. The changes in operating assets and liabilities were due primarily to the decrease in accounts receivable, inventories, prepaid expenses and other current assets, and in the amount due from affiliates, and an increase in accrued expenses and other payables, all of which were partially offset by an increase in accounts receivable, other, an increase in deferred tax asset, net, an increase in other assets, net, and a decrease in accounts payable. The decrease in accounts receivable was primarily due to a decrease in credit sales and our increased collection efforts. Inventories decreased primarily due to changes in our product mix and our efforts to improve our levels of inventory on hand. The decrease in prepaid expenses and other current assets was primarily due to the timing of insurance policy renewals. The decrease in amounts due from affiliates, net, was based on receipt of payment of the total outstanding balance due. The increase in accounts receivable, other, was primarily related to a non-sufficient fund check received from a customer and was partially offset by reimbursement received from a customer, which exceeded customary credit terms, for product and mass chain shelving requirements that we advanced. The increase in accrued expenses and other payables resulted from the timing of vendor payments. The increase in deferred tax asset, net, was based on payment of income taxes. The increase in other assets, net, resulted from an increase in contract related reimbursements. The decrease in accounts payable resulted primarily from the timing of vendor payments.

Investing Activities

Net cash used in investing activities was approximately $1.6 million for the nine months ended December 31, 2008, as compared to net cash used of approximately $12.5 million for the nine months ended December 31, 2007. The change in the nine months ended December 31, 2008 was due primarily to leasehold improvement and equipment purchases, intangible asset purchases and usage related to the minority interest associated with American Antibiotics plant in Baltimore, Maryland, all of which was partially offset by proceeds from redemption of a certificate of deposit and repayments of notes receivable.

Financing Activities

Net cash provided by financing activities was approximately $5.3 million for the nine months ended December 31, 2008, as compared to net cash provided by financing activities of approximately $13.1 million for the nine months ended December 31, 2007. The change in the nine months ended December 31, 2008 was primarily attributable to proceeds received from private placement convertible debt, net advances on our revolving credit facility, proceeds received from the issuance of a note for equipment purchased, proceeds from the issuance of a related party obligation and proceeds from stock options exercised, all of which were partially offset by payments of private placement fees, payments of short-term obligations and payments of long-term obligations.

In light of our default on our obligations with Wachovia and Whitebox, we believe that cash expected to be generated from operations, current cash reserves, and existing financial arrangements is not sufficient to meet our capital expenditures and working capital needs for our operations as presently conducted. Our future liquidity and cash requirements will depend on a wide range of factors, including the level of business in existing operations, expansion of facilities, expected results from recent procedural changes surrounding the acceptance of manufacturing sales orders, and possible acquisitions. In particular, we have added additional manufacturing lines and have purchased additional fully automated manufacturing equipment to meet our present and future growth. Our plans may require the leasing of additional facilities and/or the leasing or purchase of additional equipment in the future to accommodate further expansion of our manufacturing, warehousing and related storage needs.

Although we are actively involved in negotiations with Whitebox to reach a mutually acceptable arrangement to restructure the financing, there can be no assurance that we will reach a mutually acceptable arrangement. We are continuing to attempt to reduce expenses and are seeking alternate financing arrangements to satisfy the Wachovia obligations with other potential lenders and to refinance all of our facilities. Again, there can be no assurance that we will be able to obtain additional or alternative financing on terms acceptable to us or at all, particularly in light of the current economic and financial market environment. We are considering all available alternatives.

If we are unable to achieve consistent profitability, additional steps will have to be taken in order to maintain liquidity, including plant consolidations and additional work force reductions (see Strategic and Other Activities above). Instability in the financial markets, as a result of a recession or other factors, also may affect the cost of capital and our ability to raise capital. We are already experiencing the impact of both. The uncertainty in the capital and credit markets may hinder our ability to generate additional financing in the type or amount necessary to pursue our objectives.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are not exposed to significant interest rate or foreign currency exchange rate risk.

Item 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

Our principal executive and principal financial officers have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a – 15(e) and 15d – 15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this quarterly report. They have concluded that, based on such evaluation, our disclosure controls and procedures were effective as of December 31, 2008, as further described below.

Management’s Quarterly Report on Internal Control Over Financial Reporting

Overview

Internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) refers to the process designed by, or under the supervision of, our principal executive officer and principal financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company.

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

Management has used the framework set forth in the report entitled “Internal Control — Integrated Framework” published by the Committee of Sponsoring Organizations (“COSO”) of the Treadway Commission to evaluate the effectiveness of the Company’s internal control over financial reporting. Management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2008.

Management’s Assessment

We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired control objectives and we are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Our management evaluated, under the supervision and with the participation of our CEO and our CFO, the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2008.

Based upon this evaluation, our CEO and CFO have concluded that our current disclosure controls and procedures are effective to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and accumulated and communicated to our senior management, including our CEO and CFO, to allow timely decisions regarding required disclosures. This Quarterly Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this Quarterly Report.

PART II—OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS.

On September 29, 2006, Schering Corporation (“Schering”) filed an action in the United States District Court for the District of New Jersey, against Belcher Pharmaceuticals, Inc. and GeoPharma, Inc. (along with nineteen other defendants) alleging that the filing of Belcher Pharmaceuticals’ Abbreviated New Drug Application (“ANDA”) for 5 mg Desloratadine Tablets, AB-rated to Clarinex ^® , infringed U.S. Patent No. 6,100,274 (“the ‘274 patent”) Case No. 3:06-cv-04715-MLC-TJB. On November 8, 2006, Belcher filed a motion to dismiss in the New Jersey case for lack of jurisdiction. On October 5, 2006 Schering filed an action in the United States District Court for the Middle District of Florida, Tampa Division, Case No. 8:06-cv-01843-SCB-EAJ, against Belcher Pharmaceuticals, Inc. and GeoPharma, Inc. alleging that the filing of Belcher Pharmaceuticals’ ANDA for 5 mg Desloratadine Tablets, AB-rated to Clarinex ^® , infringed the ‘274 patent. On February 14, 2008 Belcher and Schering entered into a stipulation to withdraw the motion to dismiss the New Jersey action and to consolidate the New Jersey and Florida actions.

On February 20, 2008, Sepracor Inc. and University of Massachusetts (“Sepracor”) filed an action in the United States District Court for the District of New Jersey, against Belcher Pharmaceuticals, Inc. and GeoPharma, Inc. alleging that the filing of Belcher Pharmaceuticals’ ANDA for 5 mg Desloratadine Tablets, AB-rated to Clarinex ^® , infringed U.S. Patent No. 7,214,683 (“the ‘683 patent”) and U.S. Patent No. 7,214,684 (“the ‘684 patent”) Case No. 3:08-cv-00945-MLC-TJB.

The Company had earlier filed a Paragraph IV certification to, among other, U.S. Patent Nos. 6,100,274, 7,214,683 and 7,214,684, contesting that these patents were either invalid or had not been infringed upon, which resulted in the subsequent litigation by Schering and Sepracor.

On January 15, 2009, the Company and Belcher reached an agreement with Schering and Sepracor settling all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg), with the Company receiving a license under all relevant parents.

Under the terms of the settlement, the Company can commercially launch its generic Desloratadine product, with 6 month marketing co-exclusivity, on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. The Company’s product is pending FDA approval and seeks an AB-rating as equivalent to Schering’s Clarinex ^® tablets indicated for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis.

During September 2006, the Company, through its 51% owned subsidiary, American Antibiotics, LLC, filed in the Circuit Court for Anne Arundel County, Maryland, Case No. C-06-117230, naming defendents Consolidated Pharmaceutical Group (“CPG”), the directors of CPG and two other individuals acting on behalf of CPG (collectively “the Defendents”). The litigation arises from and relates to agreements entered into between American Antibiotics and CPG for the purchase by American Antibiotics all of CPG’s rights, title and interest in various pharmaceutical Abbreviated New Drug Applications (“ANDAs”) and for the Baltimore Maryland facility lease (the “Lease”). The Suit brought by the Company alleges that the Defendents breached the ANDA agreement with certain misrepresentations and by failing to perform all the required improvements and modifications to the Baltimore, Maryland facility. Consolidated with American Antibiotic’s lawsuit is a separate action file against it by CPG, alleging that American Antibiotics has failed to pay rent that is due and owing under the Lease. Both cases have been stayed pending the outcome of settlement discussions, which are ongoing between the parties.

On May 1, 2006 Esther Krausz and Sharei Yeshua (“Note Holders”) filed an action against Dynamic Health Products, Inc. in the Circuit Court of Broward County, Florida (Index No. 06-6187) alleging Dynamic Health Products, Inc. defaulted on note payment obligations. The face amount of the note alleged to be held by Ester Krausz totals $280,000, the face amount of the note alleged to be held by Sharei Yeshua totals $220,000. The notes contain an interest rate of 8% per annum. Preliminary discovery has been conducted. Dynamic Health Products, Inc. filed a third party action against the agent for the Note Holders seeking indemnity and that action was settled in May 2008. The Note Holders have filed a request for trial with the court but no date has been set. Dynamic Health Products, Inc. is investigating whether the purported agent made any payments to the Note Holders on behalf of Dynamic Health Products, Inc. without disclosing those payments. To date, Plaintiffs have not provided copies of the notes to Dynamic Health Products, Inc. or made a specific monetary demand. Dynamic Health Products, Inc. intends to vigorously defend itself in this action.

From time to time the Company is subject to litigation incidental to its business including possible product liability claims. Such claims, if successful, could exceed applicable insurance coverage.

The Company is, from time to time, involved in litigation relating to claims arising out of its operations in the ordinary course of business. The Company believes that none of the claims that were outstanding as of December 31, 2008 and March 31, 2008 should have a material adverse impact on its financial condition or results of operations.

Item 1A. RISK FACTORS.

In addition to other information set forth in this Report, you should carefully consider the risk factors previously disclosed in “Item 1A. to Part I” of our Annual Report on Form 10-K for the year ended March 31, 2008. We do not believe there have been any material changes in our risk factors since the filing of our Annual Report on Form 10-K for the year ended March 31, 2008 other than additional risks related to worldwide economic and industry conditions. However, we may update our risk factors in our SEC filings from time to time for clarification purposes or to include additional information, at management’s discretion, even when there have been no material changes. The following risk factor is being added to provide additional information.

The Demand for Our Products and Our Business May be Adversely Affected by Worldwide Economic and Industry Conditions: Our business is affected by economic and industry conditions and our revenues are dependent upon demand for our products. Demand, in turn, is impacted by industry cycles and the availability of end user discretionary income, both of which can dramatically affect our business. These cycles may be characterized by decreases in product demand, excess customer inventories, and accelerated erosion of prices. The global economy is currently in recession and we first began to see adverse effects of this in our fiscal quarter ended September 30, 2008, as the reduction in end user demand for our products caused a reduction in demand for our products by our customers. We believe the further weakening of the U.S. and global economy and the continued stress in the financial markets has deepened the current economic downturn and caused a significant decrease in demand for our products during the fiscal quarter ended December 31, 2008, as our revenues decreased over 18% from the previous fiscal quarter.

If global economic conditions remain uncertain or deteriorate further, we may experience additional material adverse effects on our future revenues, cash flows and financial position. A prolonged global recession may have other adverse effects on us, such as:

• The ability of our customers to pay their obligations to us may be adversely affected, which could cause a negative impact on our cash flows and our results of operations;

• The carrying value of our goodwill and other intangible assets may decline in value, which could harm our financial position and results of operations;

• Our suppliers may not be able to fulfill their obligations to us, which could harm our manufacturing process and our business; and

• The uncertainty in the capital and credit markets may hinder our ability to generate additional financing in the type or amount necessary to meet our obligations or pursue our objectives.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

On October 16, 2008, the Company held its 2008 annual meeting of stockholders (the “Meeting”). At the Meeting, all proposals presented were approved by the Company’s shareholders. The following is a tabulation of the voting on the proposals presented at the Meeting:

Proposal No. 1: The following nominees were elected as directors of the Company, to serve as a class of directors until the 2011 Annual Meeting of Stockholders or until his successor is elected and qualified.

Name	Shares Voted For	Shares Withheld
Mihir K. Taneja	11,793,217	359,444
Dr. Kotha S. Sekharam	11,791,617	361,044
Shan Shikarpuri	11,799,216	353,445
George L. Stuart, Jr.	11,739,052	413,609

The other directors whose terms of office continue, based on staggered terms in accordance with the Company’s By-Laws, are Jugal K. Taneja, Carol Dore-Falcone, Dr. Barry H. Dash, William L. LaGamba, Dr. Rafick Henein, A. Theodore Stautberg and Mandeep K. Taneja.

Proposal No. 2: A proposal to ratify the selection of Brimmer, Burek & Keelan LLP as the Company’s independent auditors for the fiscal year ending March 31, 2009 was approved as follows:

Shares Voted For	Shares Voted Against	Shares Abstaining
12,009,150	107,196	36,315

Item 5. OTHER INFORMATION.

(a) Not applicable.

(b) None.

Item 6. EXHIBITS

Exhibits

The following Exhibits are filed as part of this Report:

Exhibit Number	Description
3.1	Articles of Incorporation of Energy Factors, Inc., filed September 3, 1985. (1)**
3.2	By-Laws of GeoPharma, Inc. (4)**
3.3	Articles of Amendment to Articles of Incorporation of Innovative Companies, Inc., changing name. (4)**
3.4	Certificate of Designation of Series B preferred stock. (2)**
10.1	Form of Employment Agreement with Mihir K. Taneja, dated as of April 1, 2008. (4)**
10.2	Form of Employment Agreement with Kotha S. Sekharma, Ph.D., dated as of April 1, 2008. (4)**
10.3	Form of Employment Agreement with Carol Dore-Falcone, dated as of April 1, 2008. (4)**
10.4	Form of Employment Agreement with Mandeep K. Taneja, dated as of April 1, 2008. (4)**
10.5	Form of Consulting Agreement with Jugal K. Taneja, dated as of April 1, 2008. (4)**
10.6	Change in Terms Agreement between the Company and First Community Bank of America, dated April 6, 2008. (4)**
10.7	Amended and Restated Secured Convertible Note Purchase Agreement between the Company and Whitebox Pharmaceutical Growth Fund, Ltd., dated April 24, 2008. (3)**
10.8	Amended and Restated 12% Secured Convertible Promissory Note issued by the Company to Whitebox Pharmaceutical Growth Fund, Ltd., dated April 24, 2008. (3)**
10.9	Amended and Restated Registration Rights Agreement between the Company and Whitebox Pharmaceutical Growth Fund, Ltd., dated April 23, 2008. (3)**
10.10	Modification Number 001 to Promissory Note between Bob O’Leary Health Food Distributor Co., Inc., Dynamic Marketing I, Inc. and Wachovia Bank, National Association, dated as of April 25, 2008. (4)**
10.11	Allonge To Promissory Note between Bob O’Leary Health Food Distributor Co., Inc., Dynamic Marketing I, Inc. and Wachovia Bank, National Association, dated as of August 28, 2008. (5)**
10.12	Allonge To Promissory Note between Bob O’Leary Health Food Distributor Co., Inc., Dynamic Marketing I, Inc. and Wachovia Bank, National Association, dated as of August 28, 2008. (5)**
10.13	Promissory Note issued by the Company to First Community Bank of America, dated September 30, 2008. (5)**
10.14	Settlement Agreement between Schering Corporation, Belcher Pharmaceuticals, Inc. and the Company, dated January 15, 2009.
31.1	Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.
31.2	Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

** Previously filed

1. Filed as an exhibit to the Company’s Form SB-2 filed with the Securities and Exchange Commission on December 15, 1999 and incorporated herein by reference.

2. Filed as an exhibit to the Company’s Form 8-K filed with the Securities and Exchange Commission on February 13, 2004 and incorporated herein by reference.

3. Filed as an exhibit to the Company’s Form 8-K filed with the Securities and Exchange Commission on April 30, 2008 and incorporated herein by reference.

4. Filed as an exhibit to the Company’s Form 10-K filed with the Securities and Exchange Commission on June 30, 2008 and incorporated herein by reference.

5. Filed as an exhibit to the Company’s Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008 and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GeoPharma, Inc.
Date: February 13, 2009	By:	/s/ Mihir K. Taneja
		Mihir K. Taneja
		Chief Executive Officer, Secretary and Director
		(Principal Executive Officer)
Date: February 13, 2009	By:	/s/ Carol Dore-Falcone
		Carol Dore-Falcone
		Senior Vice President, Chief Financial Officer and Director
		(Principal Financial and Accounting Officer)

EX-10.14

Exhibit 10.14

SETTLEMENT AGREEMENT

This Settlement Agreement (including Exhibits A through C, the “Agreement”) is made and entered into this 15th day of January, 2009 (the “Effective Date”), by and between, on the one hand, Schering Corporation (“Schering”), and on the other hand, Belcher Pharmaceuticals, Inc. and GeoPharma, Inc. (collectively, “Belcher”) (collectively, the “Parties,” or each separately, a “Party”).

RECITALS

A. WHEREAS Schering owns U.S. Patent No. 6,100,274 (“the ’274 Patent”), which covers CLARINEX^® brand desloratadine 5 milligram tablets, which product Schering sells in the United States of America, including its territories, possessions and the Commonwealth of Puerto Rico (the “Territory”), under NDAs 21-165, 21-297, and 21-363;

B. WHEREAS Schering is the exclusive licensee of Sepracor Inc. (“Sepracor”) with respect to certain patents relating to desloratadine, including U.S. Patent Nos. 7,214,683 (“the ’683 Patent”) and 7,214,684 (“the ’684 Patent”) (collectively, the “Sepracor Patents”);

C. WHEREAS, under the license agreement between Schering and Sepracor, Schering has the right to sublicense the Sepracor Patents under certain conditions;

D. WHEREAS Belcher has sought approval from the U.S. Food and Drug Administration (“FDA”) to market the generic desloratadine 5 milligram tablet product that is the subject of ANDA 78-355 (the “Belcher ANDA”);

E. WHEREAS Schering has prosecuted, and Belcher has defended, an action for patent infringement in the United States District Court for the District of New Jersey (the “Court”), Schering Corp. v. Zydus Pharmaceuticals, USA, Inc. et al., Civil Action No. 06-4715 (D.N.J.), and an action for patent infringement in the United States District Court for the Middle District of Florida, Schering Corp. v. GeoPharma, Inc. et al., Civil Action No. 06-1843 (M.D. Fla.), regarding the Belcher ANDA and the proposed generic product defined therein, which actions were consolidated for all pre-trial proceedings in In re Desloratadine Patent Litigation, MDL No. 1851, Civil Action No, 07-3930 (D.N.J.) (the “Schering Action”);

F. WHEREAS Sepracor has prosecuted, and Belcher has defended, an action for patent infringement in the Court regarding the Belcher ANDA and the proposed generic product defined therein, which action is captioned Sepracor Inc. et al. v. GeoPharma, Inc. et al., Civil Action No. 08-945 (D.N.J.) (the “Sepracor Action”);

G. WHEREAS, subject to the terms and conditions herein, Schering has agreed to grant Belcher a non-exclusive license and sublicense, as applicable, to manufacture and distribute the generic desloratadine product that is the subject of the Belcher ANDA in the Territory as of the date, and upon the terms, set forth in the License Agreement defined and referred to in Section 2 of this Agreement; and

H. WHEREAS the Parties are willing to settle the Schering Action on the terms set forth herein.

NOW THEREFORE, in consideration of the promises and mutual covenants set forth herein, the sufficiency of which are hereby acknowledged, the Parties hereby agree as follows.

1. Stipulation And Order. In consideration of the mutual benefits of entering into this Agreement, the Parties shall enter into and cause to be filed with the Court, within one (1) day of the Effective Date, a stipulation and order dismissing, without prejudice, all claims, defenses and counterclaims as between Belcher and Schering and providing, inter alia, that each Party will assume its own costs and expenses, including attorney fees, in connection with the Schering Action, substantially in the form annexed hereto as Exhibit A (the “Stipulation And Order”). If the Court does not grant the Stipulation And Order substantially in the form annexed hereto as Exhibit A, the Parties agree to confer in good faith and revise that document consistent with the requirements of the Court.

2. License Agreement. Contemporaneously with the execution of this Agreement, Schering and Belcher shall enter into a non-exclusive license and sublicense agreement in the form annexed hereto as Exhibit B (the “License Agreement”).

3. Legal Fees. Consistent with the Stipulation And Order, each Party shall pay its own costs and expenses, including attorney fees, incurred in connection with the Schering Action and in connection with the preparation and execution of this Agreement.

4. Legal Compliance. The Parties shall submit this Agreement, the License Agreement, and the Stipulation And Order (the “Settlement Documents”) to the appropriate personnel at the Federal Trade Commission (“FTC”) and the Antitrust Division of the Department of Justice (the “DOJ”) as soon as practicable after the Effective Date and in no event later than three (3) days after the Effective Date.

    (a) To the extent that any legal or regulatory issues or barriers arise with respect to the Settlement Documents, or any subpart thereof, the Parties shall use commercially reasonable efforts to modify the Settlement Documents to address any such legal or regulatory issues (including for example any objections by the FTC or DOJ) while maintaining the material terms of the transaction. Should the FTC or DOJ, as the case may be, object to any such modifications, the Parties agree to continue to use commercially reasonable efforts to modify, as many times as necessary, the Settlement Documents as required above in this Section 4.

For purposes of the Settlement Documents, “commercially reasonable efforts” shall mean the reasonable, diligent and good-faith efforts as such Party would normally use to accomplish a similar objective under similar circumstances.

5. Released Claims. In addition to the dismissal of the Schering Action, as set forth in the Stipulation And Order, Belcher and Schering make the following releases, which shall be effective upon the grant of the Stipulation And Order by the Court in the Schering Action: (a) Belcher for itself and its Affiliates hereby irrevocably releases and discharges Schering and its Affiliates, successors, assigns, directors, officers, employees, agents and customers from all causes of action, demands, claims, damages and liabilities of any nature, whether known or unknown, arising between Belcher and/or its Affiliates and Schering and/or its Affiliates from or in connection with the Schering Action, the Sepracor Action or the Belcher ANDA, occurring

2

prior to the Effective Date of this Agreement, including, without limitation, all claims that Belcher has asserted or could have asserted in the Schering Action, the Sepracor Action or in any judicial proceeding that the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement, is somehow invalid, unenforceable or not infringed by the sale of the generic desloratadine product that is the subject of the Belcher ANDA in the Territory (all of the above collectively, the “Belcher Released Claims”); (b) Schering for itself and its Affiliates hereby irrevocably releases and discharges Belcher and its Affiliates, successors, assigns, directors, officers, employees, agents, distributors, suppliers and customers from all causes of action, demands, claims, damages and liabilities of any nature, whether known or unknown, arising between Schering and/or its Affiliates and Belcher and/or its Affiliates from or in connection with the Schering Action, the Sepracor Action or the Belcher ANDA, occurring prior to the Effective Date of this Agreement, including, without limitation, all claims that Schering has asserted or could have asserted in the Schering Action, the Sepracor Action or in any judicial proceeding that the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement, is infringed by the Belcher ANDA (all of the above collectively, the “Schering Released Claims”); (c) this Agreement shall constitute a final settlement between the Parties in the Territory and, provided Schering does not assert or institute any new litigation against Belcher with respect to the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement, with respect to the Belcher ANDA pursuant to Section 4.6 of the License Agreement, neither Belcher nor its Affiliates or agents shall institute any new litigation against Schering with respect to the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement, and any proposed generic equivalent of the CLARINEX^® brand desloratadine 5 milligram tablet product or assist or cooperate with any other party in any litigation against Schering with respect to any such litigation referred to above unless so ordered by the Court or compelled by law; (d) Belcher shall not release any agent or consultant retained solely by Belcher (whether retained for Belcher’s benefit by Belcher or by any Belcher attorney) to assist or cooperate with any litigant in any litigation against Schering with respect to the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement, and shall not release any attorney who represented Belcher in the Schering Action from maintaining the confidentiality of non-public information to which such attorney had access in connection with the Schering Action or grant any waivers with respect to such maintenance unless so ordered by the Court or compelled by law; and (e) to the extent necessary, Belcher shall permit and cooperate .with Schering to enforce the obligations of such agents, consultants or attorneys referred to under Section 5(d) herein. The Schering Released Claims do not preclude Schering from asserting infringement of the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement, in any action against Belcher involving future Belcher products other than the Licensed Product, as defined in the License Agreement. The Belcher Released Claims do not preclude Belcher from challenging the validity, enforceability and/or infringement of the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement in any action involving future Belcher products other than the Licensed Product, as defined in the License Agreement.

3

6. ACKNOWLEDGMENTS. Belcher and Schering acknowledge as follows:

(a) BELCHER ACKNOWLEDGES THAT IT MAY HEREAFTER DISCOVER CLAIMS OR FACTS IN ADDITION TO OR DIFFERENT FROM THOSE WHICH IT NOW KNOWS OR BELIEVES TO EXIST WITH RESPECT TO THE BELCHER RELEASED CLAIMS, THE FACTS AND CIRCUMSTANCES ALLEGED IN THE SCHERING ACTION AND SEPRACOR ACTION, AND/OR THE SUBJECT MATTER OF THIS AGREEMENT, WHICH, IF KNOWN OR SUSPECTED AT THE TIME OF EXECUTING THIS AGREEMENT, MAY HAVE MATERIALLY AFFECTED THIS AGREEMENT. NEVERTHELESS, UPON THE EFFECTIVENESS OF THE RELEASE OF THE BELCHER RELEASED CLAIMS AS SET FORTH IN SECTION 5 ABOVE, BELCHER HEREBY ACKNOWLEDGES THAT THE BELCHER RELEASED CLAIMS INCLUDE WAIVERS OF ANY RIGHTS, CLAIMS OR CAUSES OF ACTION THAT MIGHT ARISE AS A RESULT OF SUCH DIFFERENT OR ADDITIONAL CLAIMS OR FACTS. BELCHER ACKNOWLEDGES THAT IT UNDERSTANDS THE SIGNIFICANCE AND POTENTIAL CONSEQUENCES OF SUCH A RELEASE OF UNKNOWN UNITED STATES JURISDICTION CLAIMS AND OF SUCH A SPECIFIC WAIVER OF RIGHTS. BELCHER INTENDS THAT THE CLAIMS RELEASED BY IT UNDER THIS RELEASE BE CONSTRUED AS BROADLY AS POSSIBLE TO THE EXTENT THEY RELATE TO UNITED STATES JURISDICTION CLAIMS. BELCHER IS AWARE OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS;

“A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her, must have materially affected his or her settlement with the debtor.”

BELCHER AGREES TO EXPRESSLY WAIVE ANY RIGHTS IT MAY HAVE UNDER THIS CODE SECTION OR UNDER FEDERAL, STATE OR COMMON LAW STATUTES OR JUDICIAL DECISIONS OF A SIMILAR NATURE, AND KNOWINGLY AND VOLUNTARILY WAIVES SUCH UNKNOWN CLAIMS.

(b) SCHERING ACKNOWLEDGES THAT IT MAY HEREAFTER DISCOVER CLAIMS OR FACTS IN ADDITION TO OR DIFFERENT FROM THOSE WHICH IT NOW KNOWS OR BELIEVES TO EXIST WITH RESPECT TO THE SCHERING RELEASED CLAIMS, THE FACTS AND CIRCUMSTANCES ALLEGED IN THE SCHERING ACTION AND SEPRACOR ACTION, AND/OR THE SUBJECT MATTER OF THIS AGREEMENT, WHICH, IF KNOWN OR SUSPECTED AT THE TIME OF EXECUTING THIS AGREEMENT, MAY HAVE MATERIALLY AFFECTED THIS AGREEMENT. NEVERTHELESS, UPON THE EFFECTIVENESS OF THE RELEASE OF THE SCHERING RELEASED CLAIMS AS SET FORTH IN SECTION 5 ABOVE, SCHERING HEREBY ACKNOWLEDGES THAT THE SCHERING RELEASED CLAIMS INCLUDE WAIVERS OF ANY RIGHTS, CLAIMS OR CAUSES OF ACTION THAT MIGHT ARISE AS A RESULT OF SUCH DIFFERENT OR ADDITIONAL CLAIMS OR FACTS. SCHERING ACKNOWLEDGES THAT IT UNDERSTANDS THE SIGNIFICANCE AND POTENTIAL CONSEQUENCES OF SUCH A RELEASE OF UNKNOWN UNITED STATES JURISDICTION CLAIMS AND OF SUCH A SPECIFIC WAIVER OF RIGHTS. SCHERlNG INTENDS THAT THE CLAIMS RELEASED BY IT UNDER THIS RELEASE BE CONSTRUED AS BROADLY AS POSSIBLE TO THE EXTENT THEY RELATE TO

4

UNITED STATES JURISDICTION CLAIMS. SCHERING IS AWARE OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:

“A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her, must have materially affected his or her settlement with the debtor.”

SCHERING AGREES TO EXPRESSLY WAIVE ANY RIGHTS IT MAY HAVE UNDER THIS CODE SECTION OR UNDER FEDERAL, STATE OR COMMON LAW STATUTES OR JUDICIAL DECISIONS OF A SIMILAR NATURE, AND KNOWINGLY AND VOLUNTARILY WAIVES SUCH UNKNOWN CLAIMS.

7. No Interference But No Consent For FDA Approval. Subject to Belcher’s compliance with the terms of this Agreement and the License Agreement, and excluding any safety or efficacy concerns relating to the generic product defined by the Belcher ANDA, Schering shall not initiate any activity directly against the generic product defined by the Belcher ANDA to interfere with Belcher’s efforts to: (a) obtain FDA approval of the Belcher ANDA; or (b) launch the generic product that is the subject of the Belcher ANDA as of the date and under the terms provided by the License Agreement. Neither this Agreement nor this section shall be interpreted as Schering consenting to approval from the FDA or any other applicable regulatory authority for Belcher to market a product incorporating desloratadine in the Territory.

8. Confidentiality. The terms of this Agreement shall be maintained in strict confidence by the Parties; except: (a) as provided by Section 4 of this Agreement; (b) that Schering may disclose any and all terms of this agreement to Sepracor; (c) that Schering may disclose such terms as may be necessary or useful in connection with any litigation or other legal proceeding relating to the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement; (d) that either Party may disclose such terms if and as required by law, including, without limitation, SEC reporting requirements, or by the rules or regulations of any stock exchange that the Parties are subject to; (e) that Belcher may disclose such terms to the FDA as may be necessary or useful in obtaining and maintaining final approval of the Belcher ANDA and launching the generic product that is the subject of the Belcher ANDA as provided by the License Agreement, so long as Belcher requests that the FDA maintain such terms in confidence; and (f) that the Parties may each issue a press release disclosing that the Parties have settled the Schering Action, and that Belcher has received a license to the ’274 Patent, and a sublicense to the ’683 Patent and ’684 Patent, that will permit Belcher to commercially launch its generic desloratadine product on July 1,2012, or earlier in certain circumstances, and that such launch will be of a prescription or over-the-counter Licensed Product, as defined by the License Agreement, depending on whether Schering is selling at the time of such launch a prescription or over-the-counter NDA Product or Modified NDA Product, as defined by the License Agreement, so long as such press release is approved by the other Party, which approval shall not be unreasonably withheld. In its press release described by Section 8(f)), Belcher may additionally mention any settlement of the Sepracor Action that has been agreed to between Belcher and Sepracor Inc. The Parties acknowledge and agree that, upon its filing with the Court, the Stipulation And Order will be a matter of public record and shall not be subject to any confidentiality restrictions. The Parties further agree that, upon the filing of the

5

Stipulation And Order with the Court, the fact that the Parties have settled the Schering Action will be a matter of public record and shall not be subject to any confidentiality restrictions, but the terms of such settlement shall be maintained in confidence as provided by this Section 8.

9. Term and Termination. This Agreement shall continue from the Effective Date until the earlier of: (a) the expiration of the last to expire of the Licensed Patents, as defined by the License Agreement; or (b) the date of a Final Court Decision or Decisions, as defined by the License Agreement, that all of the claims of the Licensed Patents, as defined by the License Agreement, are invalid or unenforceable. The releases and discharges set forth in Section 5 of this Agreement shall survive the termination of this Agreement and the confidentiality obligations set forth in Section 8 above shall survive for a period of twenty (20) years from the Effective Date, notwithstanding any earlier expiration or termination of this Agreement. The License Agreement shall remain in full force and effect pursuant to its own terms notwithstanding the expiration or termination of this Agreement.

10. No Assignment. This Agreement may not be assigned or transferred to a third party without the express prior written consent of the other Parties hereto, except to a successor to all or substantially all of the business of the assigning or transferring Party to which this Agreement pertains (whether by sale of stock, merger, consolidation or otherwise) in which case the Party shall assign this Agreement to such successor, provided that a Party may in the ordinary course of its business assign its rights under this Agreement to an Affiliate or may transfer the rights under this Agreement from one Affiliate to another without the prior consent of the other Party. The covenants, rights and obligations of a Party under this Agreement shall remain binding upon the transferring Party and shall inure to the benefit of and be binding upon any successor or permitted assignee of the Party and any assignee of Schering’s ownership of, or exclusive license to, the ’274 Patent, the ’683 Patent and/or the ’684 Patent or any of the other Licensed Patents, as defined in the License Agreement.

11. Notice. Any notice required or permitted to be given or sent under this Agreement shall be hand delivered or sent by express delivery service or certified or registered mail, postage prepaid, to the Parties at the addresses indicated below.

If to Schering, to:	Henry Hadad
	Vice President & Associate General Counsel, Intellectual Property
	Schering Corporation
	2000 Galloping Hill Road
	Kenilworth, New Jersey 07033
with copies to:	Peter J. Armenio
	Kirkland & Ellis LLP
	153 East 53rd Street
	New York, New York 10022
If to Belcher, to:	Mandeep Taneja
	GeoPharma, Inc.
	6950 Bryan Dairy Road
	Largo, FL 33777

6

with copies to:	David Rosen
	Foley & Lardner LLP
	3000 K Street, NW, Suite 500
	Washington, DC 20007
If to GeoPharma, to:	Mandeep Taneja
	GeoPharma, Inc.
	6950 Bryan Dairy Road
	Largo, FL 33777
with copies to:	David Rosen
	Foley & Lardner LLP
	3000 K Street, NW, Suite 500
	Washington, DC 20007

Any such notice shall be deemed to have been received on the date actually received. Either Party may change its address by giving the other Party written notice, delivered in accordance with this Section.

12. Entire Agreement. This Agreement, as defined herein to include Exhibits A through C, constitutes the complete, final and exclusive agreement between the Parties with respect to the subject matter hereof and supersedes and terminates any prior or contemporaneous agreements and/or understandings between the Parties, whether oral or in writing, relating to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement. No subsequent alteration, amendment, change, waiver or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. Each Party in deciding to execute this Agreement has retained counsel and bas not relied on any understanding, agreement, representation or promise by the other Party that is not explicitly set forth herein.

13. Governing Law. This Agreement shall be governed, interpreted and construed in accordance with the laws of the State of New Jersey, without giving effect to choice of law principles. Subject to the arbitration provisions of the License Agreement, the Parties irrevocably agree that the federal district court in the State of New Jersey shall have exclusive jurisdiction to deal with any disputes arising out of or in connection with this Agreement and that, accordingly, any proceedings arising out of or in connection with this Agreement not subject to arbitration shall be brought in the United States District Court for the District of New Jersey. Notwithstanding the foregoing, if there is any dispute that is not subject to arbitration and for which the federal district court in the State of New Jersey does not have subject matter jurisdiction, the state courts in New Jersey shall have jurisdiction. In connection with any dispute arising out of or in connection with this Agreement that is not subject to arbitration, each Party hereby expressly consents and submits to the personal jurisdiction of the federal and state courts in the State of New Jersey.

7

14. Severability. Subject to the provisions and the mechanisms of Section 4 above, if any provision of this Agreement is declared illegal, invalid or unenforceable by a court having competent jurisdiction, it is mutually agreed that this Agreement shall endure except for the part declared invalid or unenforceable by order of such court; provided, however, that in the event that the terms and conditions of this Agreement are materially altered, the Parties will, in good faith, renegotiate the terms and conditions of this Agreement to reasonably replace such invalid or unenforceable provisions in light of the intent of this Agreement.

15. Third Party Benefit. Belcher acknowledges that Sepracor is an intended third party beneficiary of the indemnity in Section 8.1 of the License Agreement and has a direct right of action against Belcher to enforce the terms and conditions of that indemnity. Other than the indemnity in Section 8.1 of the License Agreement, no other provision of this Agreement shall be deemed to be for the benefit of, or enforceable by, any third party, except as provided by Section 10 of this Agreement.

16. Waiver. Any delay or failure in enforcing a Party’s rights under this Agreement, or any acquiescence as to a particular default or other matter, shall not constitute a waiver of such Party’s rights to the enforcement of such rights, nor operate to bar the exercise or enforcement thereof at any time or times thereafter, except as to an express written and signed waiver as to a particular matter for a particular period of time.

17. Counterparts. This Agreement shall become binding when anyone or more counterparts hereof, individually or taken together, bears the signatures of each of the Parties hereto. This Agreement may be executed in any number of counterparts (including facsimile counterparts), each of which shall be an original as against a Party whose signature appears thereon, but all of which taken together shall constitute one and the same instrument.

18. Representations and Warranties. The Parties hereby represent and warrant that: (a) they have approved the execution of this Agreement and have authorized and directed the signatory officers below to execute and deliver this Agreement; (b) they each have the full right and power to enter into this Agreement, and there are no other persons or entities whose consent or joinder in this Agreement is necessary to make fully effective those provisions of this Agreement that obligate, burden or bind either of them; (c) when so executed by each Party, this Agreement shall constitute a valid and binding obligation of such Party, enforceable in accordance with its terms; and (d) they have not transferred or assigned or pledged to any third party, whether or not Affiliated, the right to bring, pursue or settle any of the claims, counterclaims or demands made in the Schering Action. Schering further represents and warrants that Schering is the exclusive licensee of the Sepracor Patents and that, under the license agreement between Schering and Sepracor, Schering has the right to sublicense the Sepracor Patents to Belcher under the terms and conditions set forth in this Agreement and the License Agreement.

19. Costs. Each Party shall bear its own costs, expenses and taxes in the performance of this Agreement, including attorney fees.

20. Construction. This Agreement has been jointly negotiated and drafted by the Parties through their respective counsel and no provision shall be construed or interpreted for or against any of the Parties on the basis that such provision, or any other provision, or the Agreement as a whole, was purportedly drafted by the particular Party. All references to periods

8

of days for taking certain actions in this Agreement shall be construed to refer to business days. All references to an Affiliate or Affiliates in this Agreement shall mean any person or legal entity controlling, controlled by or under common control with the Party with respect to which such status is at issue and shall include, without limitation, any corporation 50% or more of the voting power of which (or other comparable ownership interest for an entity other than a corporation) is owned, directly or indirectly, by a Party hereto or any corporation, person or entity that owns 50% or more of such voting power of a Party hereto.

*        *        *        *        *

IN WITNESS WHEREOF, this Agreement has been executed by the duly authorized representatives of the Parties.

SCHERING CORPORATION
By:	/s/ David Piacquad
Name:	David Piacquad
Title:	VP, Business Dev

BELCHER PHARMACEUTICALS, INC.		GEOPHARMA, INC.
By:	/s/ Mandeep K. Taneja	By:	/s/ Mandeep K. Taneja
Name:	Mandeep K. Taneja	Name:	Mandeep K. Taneja
Title:	General Counsel & VP	Title:	General Counsel & VP

9

EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Mihir K. Taneja, certify that:

1. I have reviewed this quarterly report on Form 10-Q of GeoPharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 13, 2009	By:	/s/ Mihir K. Taneja
		Mihir K. Taneja
		Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Carol Dore-Falcone, certify that:

1. I have reviewed this quarterly report on Form 10-Q of GeoPharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 13, 2009	By:	/s/ Carol Dore-Falcone
		Carol Dore-Falcone
		Senior Vice President and Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARABANES-OXLEY ACT OF 2002

In connection with the Quarterly report of GeoPharma, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mihir K. Taneja, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Mihir K. Taneja

Mihir K. Taneja

Chief Executive Officer

February 13, 2009

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARABANES-OXLEY ACT OF 2002

In connection with the Quarterly report of GeoPharma, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Carol Dore-Falcone, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:

(3) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(4) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Carol Dore-Falcone

Carol Dore-Falcone

Senior Vice President and Chief Financial Officer

February 13, 2009